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Current FDA approved anti-cytomegalovirus antivirals are ganciclovir, foscarnet, and 
cidofovir.  These drugs target the viral polymerase to inhibit DNA synthesis.  Halogenated 
benzimidazoles target a step later in viral replication during packaging and cleavage of the viral 
genome.  The compounds 2-Bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole (BDCRB) 
and 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole (TCRB) are novel inhibitors of human 
cytomegalovirus (HCMV) and resistance to these compounds are found within the human 
cytomegalovirus viral terminase.  Terminase is unique to the virus and in theory provides a good 
target for antiviral development.  Beginning with a BDCRB resistant guinea pig cytomegalovirus
 
 
xv 
observations found a single mutation located in the viral terminase gene UL89 and unique 
formation found in genomic ends.  In guinea pigs, the virus continued to produce large amounts 
of monomer.  This is in contrast to human cytomegalovirus treated with either BDCRB or 
TCRB.  Both compounds produced very little monomer DNA but created a supergenomic 
species, called monomer-plus that migrates to the apparent size of 270-kb on a pulse field gel.  A 
model was developed to explain formation of monomer plus and my project aims originated 
from the model.  In the presence of BDCRB and TCRB, packaging is relaxed resulting in the 
normal cleavage site being skipped and cleavage occurring at the next available cleavage site 
creating a short-long-short genome.  In guinea pigs, cleavage has been relaxed by premature 
cleavage of the terminal ends. 
Current antivirals do not block viral entry therefore, patients are infected with HCMV.  
Blocking entry of HCMV into cells would prevent HCMV infection.  It has been shown that 
antibodies to epitopes within the gH/gL/UL128-131 complex can block viral entry into 
endothelial, epithelial, and other cell types while antibodies to gB block entry into fibroblasts.  
The majority of the current work on entry into epithelial cells has been performed in retinal 
pigment epithelium and epithelial cells derived from tumors.  Viral entry into cell lines derived 
from mucosa cells was dependent on the complex gH/gL/UL128-131.  Rabbit antibodies raised 
against UL130 and UL131 peptides neutralized epithelial entry with effects as potent as human 
seropositive sera.  This suggests that the entry complex can be blocked by single epitopes.   
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CHAPTER 1: Introduction 
 
 In 2009, a new order Herpesvirales was established as a result of the growing numbers of 
herpesviruses discovered (31).  The order divides Herpesviruses into three families, 
Herpesviridae consisting of mammals, birds and reptiles viruses, Alloherpesviridae containing 
fish and frog viruses and Malacoherpesviridae containing bivalve viruses.  Cytomegalovirus 
(CMV) is a member of the Herpesviridae family of viruses.  Viruses in this group have double-
stranded DNA genomes enclosed in an icosahedral capsid surrounded by a protein matrix called 
tegument.  The tegument is contained within a cell-derived envelope.  Viruses of Herpesviridae 
have four common properties: 1) they encode proteins used for nucleic acid metabolism, DNA 
synthesis, and protein processing; 2) capsid assembly and DNA synthesis occur in the nucleus; 
3) the production of infectious progeny destroys host cells; and 4) in the proper host cell, all 
herpesviruses can establish latency (116).  Herpesviridae are divided into three subgroups 
alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae.  Table 1 lists some human 
viruses associated with each subfamily within the Herpesviridae family.  Alphaherpesvirinae 
contain the human causative agents for shingles, cold sores, genital herpes and chicken pox.  
Herpes simplex 1 (HSV-1) cause cold sores, genital herpes is caused by herpes simplex 2 (HSV-
2), and chicken pox and shingles are caused by varicella zoster (VZV).  Gammaherpesvirinae 
subfamily contains the human viruses, Epstein- Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus.  CMV is the prototypic 
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Table 1:  Human viruses of Herpesviridae Family.
 
Subfamily Virus Characteristics 
Alphaherpesvirinae Herpes simplex (HSV-1) 
      Type 1 and type 2 
Varicella zoster (VZV) 
 
Variable host range 
Short reproduction cycle 
Rapid spread of virus 
Destruction of host cell 
Establish latent infections 
Betaherpesvirinae Cytomegalovirus 
Roseolovirus (HHV-6 and 
HHV-7) 
Restricted host range 
Long reproduction cycle 
Long viral spread of virus 
Maintain latent infections 
Gammaherpesvirinae Epstein-Barr Virus (EBV) 
Kaposi’s sarcoma-associated 
virus 
Host range is only in natural host 
Replicate in lymphoblastoid cells 
Specific for T or B lymphocytes 
Latent virus in lymphoid tissue 
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member of the betaherpesvirinae group.  Other members of this group infecting humans include 
HHV-6 and HHV-7.  Cytomegaloviruses are species-specific and have been found in a variety of 
animals, from human and chimpanzee to mice, rats, guinea pigs and pigs.  Two of the related 
viruses that infect non-human vertebrates are murine cytomegalovirus, which infects mice, and 
guinea pig cytomegalovirus (GPCMV), which infects guinea pigs.  The newest member of the 
betaherpesvirinae is elephant endotheliotropic herpesvirus.  Viruses of the betaherpesvirinae are 
characterized by strict species-specificity and a long reproductive cycle, which leads to a slow 
infection progression.  CMV is the largest of the herpesviruses with a genome of 235-kb that 
codes for 166 to 200 genes (39). 
 
History of Human Cytomegalovirus 
In the early 20th century, pathology studies from newborns and fetuses detected a 
multisystem disease that affected the central nervous system, the liver and blood cells.  Jesionek 
and Kiolemenoglou (54, 63) reported in 1904 on abnormal cells found in the lung, kidney and 
liver of a fetus that had been reported to die from syphilis.  In the same year, Ribbert et al. (54, 
115) described similar findings in the kidney cells of a stillborn infant.  Both groups described 
large cells with a halo appearance surrounding the nucleus.  It was believed that these symptoms 
were caused by a protozoan-like infection.  Three years later, similar cells were found in the 
salivary glands of children.  The cytopathology was similar to other herpesviruses.  Cytomegalia 
was used to describe the pathology that could be caused by a viral agent (46).  In 1922, Mueller 
(89, 97) suggested that this disease could have developed before the baby was born.  Not long 
afterwards, others described the same type of multiorgan pathology found in infants and stillborn 
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and it was deduced that this phenomenon was more common than originally determined.  It was 
not until the 1950’s, with the advent of better expertise in tissue culture that human CMV 
(HCMV) could be cultured in the laboratory.  Thomas Weller at Harvard, using new tissue 
culture techniques, was interested in the protozoa, Toxoplasma gondii (54).  T. gondii can cross 
the placenta during pregnancy and the developing fetus can develop enlargement or smallness of 
the head, which can be lethal to the developing fetus.  Depending on the time of infection, the 
fetus can be miscarried or stillborn.  In healthy individuals, symptoms of toxoplasmosis are mild 
flu-like with aching muscles and fever (107).  In 1957, Weller (25) examined a liver from an 
infant believed to have congenital toxoplasmosis.  Instead of the protozoa, he identified a virus 
by the characteristic halo around the nucleus and enlarged cells.  Weller called it cytomegalic 
inclusion disease (CID) because of the enlarged cells.  In 1960, Weller gave the virus the name 
of cytomegalovirus (152).  The name cytomegalovirus is derived from Greek, cyto- meaning cell 
and megalo- meaning large.  The advent of tissue culture developments enhanced virus isolation 
and ways to diagnose this devastating disease. 
 
The significance of HCMV in human health 
HCMV is ubiquitous and usually nonpathogenic in the general population.  By age 40, 
50-80% of the population will be infected, and by age, 90 over 90% will be infected with HCMV 
(132).  The virus infects via mucosal surfaces and is transmitted by saliva, sexual contact, 
placenta transfer, breastfeeding, blood transfusion, bone marrow transplant (BMT) or solid-organ 
transplantation (SOT) (43).  For immunocompetent individuals, HCMV rarely causes serious 
illness.  When symptoms present in an immunocompetent individual during a primary infection 
the result is a mononucleosis syndrome similar to EBV with fevers for 2 to 3 weeks, muscle pain, 
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and swollen neck glands (106).  HCMV and EBV mononucleosis are clinically similar.  Neither 
is routinely treated, but if infection continues for an extended time, tests are performed to 
distinguish which virus is the causative agent (106).  After the primary infection, HCMV is 
managed by long-term immunity in the host that controls viral replication and forces the virus to 
become latent.  The major latent reservoir is uncertain, but there are indications that myeloid 
progenitors in the bone marrow are one site of latency (26).  Latent HCMV can be reactivated 
later in life, causing complications and disease to the individual especially if the immune system 
has become compromised (26).  
Three main types of immune-compromised populations are affected by HCMV; (1) organ 
transplant patients, (2) HIV/AIDS patients, and (3) congenitally infected fetuses.  In the 
immunocompromised host, infection can occur by reactivation of latent virus, reinfection, or a 
primary infection.  In transplant patients, primary infection is often acquired from the 
transplanted tissue itself or from blood products received during the procedure.  The greater the 
immunosuppression, the more severe the disease (70).  Bone marrow transplant recipients and 
AIDS patients with low CD4+ counts have the most severe symptoms (43).  These patients can 
experience graft rejection, retinitis (more common in AIDS patients), pneumonitis (more 
common in bone marrow transplant), hepatitis, esophagitis, enterocolitis, and gastritis (70).  
In solid-organ transplant (SOT) patients, HCMV can be reactivated by stress from 
surgery and sepsis.  HCMV is the most common viral pathogen that causes disease after 
transplantation.  HCMV directly causes disease in SOT patients and indirectly affects patient and 
allograft survival (111).  Greater than 50% of SOT patients develop HCMV infections, and 
within that group 10 to 50% of those patients exhibit symptoms (26).  The severity of disease 
depends on the organ being donated and the viral load within the organ (26).  Disease can 
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become more severe if the donated organ is HCMV positive and the patient is HCMV negative, 
this is referred to as tissue-invasive CMV disease.  The gastrointestinal tract is the most 
commonly affected organ.  SOT patients receive immunosuppressors to suppress their immune 
system so their body will not reject the new organ.  If they encounter HCMV, the virus will no 
longer be controlled by the immune system and will manifest as a severe disease.  Donor organs 
are not currently screened for HCMV because of the urgency of patient’s need and insufficiency 
of organs to afford the luxury of rejecting organs based on a HCMV status.  The clinical features 
in SOT patients are sudden onset of fever and malaise with a decrease in white cells and bone 
marrow suppression, termed HCMV syndrome (111).  To confirm diagnosis, HCMV DNA or 
pp65 antigen must be found in the blood.  Infected SOT patients can also develop retinitis, 
hepatitis, inflammation of the lungs, large, small intestine, and esophagus.  HCMV continues to 
play a major role in rejection of SOT patients.  Current antivirals used for SOT patients are 
limited.   
There are two methods used to overcome severe HCMV disease in SOT patients, (1) 
preemptive therapy and (2) antiviral prophylaxis.  In preemptive therapy, patients are monitored 
by PCR or antigenemia (flow cytometry) and gancicolvir is given at the first virologic sign of 
infection.  The patient is treated until HCMV has not been detected for two weeks.  The 
advantage of this approach is less exposure to antiviral toxicity to reduce the risk of resistance, 
and reduced drug costs (111).  In contrast, use of the antiviral prophylaxis method, antivirals are 
given to all patients even if HCMV has not been detected in the patient.  SOT patients are given 
gancicolvir and valganciclovir for up to six months after transplantation (111).  To assist with 
prophylaxis, HCMV immunoglobulin is given, but this is not a common practice.  While 
antiviral prophylaxis has reduced HCMV incidence by 60 to 80%, leading to a better long-life 
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survival, it can result in recurrence of HCMV after discontinuing the antiviral.  Disease has been 
detected in up to 47% of patients after stopping prophylaxis for 3 months.  This late onset of 
disease is linked to death and allograft rejection (111).  Antiviral resistance can also be 
problematic.  By using antivirals without known exposure to HCMV, the chances of developing 
resistance increase.  Patients also suffer a higher incident of side effects from the drugs. 
In patients with human immunodeficiency virus (HIV), HCMV is an opportunistic 
infection that takes advantage of the weakened immune system and HCMV has been associated 
with clinical progression of HIV.  HCMV is the most common chronic viral infection in HIV 
patients (84).  Before the introduction of highly active antiretroviral therapy (HAART), about 
40% of the adults and 9% of the children with HIV would develop AIDS because of HCMV 
infections enhancing the progression of HIV (97).  HAART was introduced in the mid-1990 and 
is a treatment of at least three active anti-retroviral medications.  Normally two nucleoside or 
nucleotide reverse transcriptase inhibitors are given plus a protease inhibitor or a non-nucleoside 
reverse transcriptase inhibitor (52).  This triple therapy is given to HIV patients to decrease the 
progression of HIV and allow the patient’s body to rebuild the damaged immune system.  
HAART often increases the CD4+ T-cell count to greater than 100 cells/µL (this is the threshold 
for HCMV infection), allowing immunocompromised patients to combat HCMV.  The most 
common organ affected by HCMV in AIDS patients is the eye, developing HCMV retinitis, 
leading to blindness.  Before HAART, about 30% of all HIV patients would develop retinitis.  
After HAART was introduced, HCMV retinitis incidence decreased from 29.4% in 1995 to 8.8% 
in 1997 (84).  As in SOT patients, the gastrointestinal tract is the second most HCMV affected 
organ.  Incidence of HCMV continues to decline with HIV patients starting HAART earlier after 
diagnoses, but the eye is still the most common HCMV-diseased organ.  While antiviral 
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treatment generally slows progression of retinitis, it rarely stops it.  With the reduction of HCMV 
infections, HIV patients can live longer with a better quality of life. 
As the leading cause of congenital viral infection in the United States, HCMV has a large 
impact on medical and public health (41).  In the United States, approximately 40,000 children 
per year are born with an active HCMV congenital infection (132).  Of these, approximately 
8,000 are symptomatic at birth and or affected with permanent disabilities.  This frequency is 
greater than Down’s syndrome (4,000 births) and Fetal Alcohol syndrome (5,000 births), yet in a 
recent survey only 22% of women were aware of HCMV and even less knew how to prevent 
HCMV transmission.  In contrast, awareness of Down’s syndrome was 97 % and Fetal Alcohol 
syndrome 83% (62).  
In congenital infections, HCMV causes damage to the central nervous system (CNS) and 
organs of perception (98).  Symptomatic newborns may have a combination of defects including 
mental retardation, cerebral palsy, sensorineural hearing loss, and impaired vision.  Progressive 
sensorineural hearing loss (SNHL) may be one of the most significant aspects of HCMV 
congenital infection in children (41).  Hearing loss can occur in children that do not display 
symptoms at birth (132).  Of the 40,000 infants born annually with HCMV infections, 32,000 are 
born asymptomatic, but of these, a significant percentage (up to 23%) will develop SNHL or 
other neurodevelopmental sequelae later in childhood (40)  
HCMV life cycle 
 HCMV is transmitted by direct contact with body fluids such as urine, saliva, or breast 
milk and is a sexually contracted disease (97).  The virus can be transferred in transplant tissues 
and blood transfusions.  Young children can shed HCMV in their urine and saliva for up to two 
years (42).  One of the best preventatives is frequent hand washing.  Mothers are advised to 
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avoid contact with children’s saliva by not sharing food, eating utensils, or kissing (106).   
 Viral entry into fibroblasts begins with the viral envelope fusing with the cell membrane 
(22, 86) (Figure 1).  In other cell types, such as endothelial and epithelial, entry occurs by 
endocytosis (50).  The viral particle is endocytosed into an endosome where fusion occurs, 
releasing the capsid into the cytoplasm.  In either case, the capsid is released into the cytoplasm 
and the particle travels by microtubules to the nuclear membrane (96).  Docking of the capsid 
occurs at nuclear pores and the viral dsDNA is released into the nucleus (21).  The dsDNA 
circularizes and replication begins, resulting in concatemers (76).  During this stage, newly made 
capsid proteins are transported into the nucleus and assembly of capsids occurs.  The 
concatemers are inserted into preformed capsids and cut into monomer lengths.  Capsids are 
sealed and are ready to leave the nucleus.  Nuclear egress occurs by envelopment through the 
inner membrane followed by a sequential deenvelopment through the outer nuclear membrane 
(83).  The DNA-containing capsid enters the cytoplasm, tegument proteins are collected around 
the capsid, and a second envelopment into vesicles occurs.  The virion continues to travel to the 
cell membrane where fusion of the vesicle membrane with cell membrane releases the virion into 
the exterior of the cell (139).  The virus is ready to infect another cell.   
Antiviral Therapies 
Ganciclovir (GCV), its prodrug valganciclovir (VGCV), foscarnet (FOS), cidofovir 
(CDV) and fomivirsen (Vitravene) are current antivirals approved for treating HCMV (126) 
(Figure 2).  The first drug to be approved was GCV, a deoxyguanosine analog.  FDA approval 
was given in 1989.  Currently, GCV is the first line of drugs to be used in treating HCMV (126) 
(Figure 2).  The first drug to be approved was GCV, a deoxyguanosine analog.  
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Figure 1: Life cycle of HCMV.  The virus enters the cell and travels by microtubules to the 
nucleus.  Linear dsDNA is released from the capsid and the DNA forms a circle and replication 
occurs by a rolling circle mechanism forming large concatemers.  Terminase (green) inserts the 
dsDNA into a preformed capsid and cleaves the dsDNA at the next appropriate cleavage site 
once a headful amount is reached.  The capsid is stabilized and sealed (orange) and egresses 
from the nucleus.  As the capsid moves through the cytoplasm, the tegument (blue and red) is 
assembled around the capsid.  As the tegument and capsid reach the cell surface, the virus exits 
the cell. 
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 The first drug to be approved was GCV, a deoxyguanosine analog.  FDA approval was given in 
1989.  Currently, GCV is the first line of drugs to be used in treating HCMV.  To be active GCV 
must be phosphorylated to its monophosphate form by the viral kinase pUL97.  Further 
phosphorylation to the triphosphate form is completed by host kinases.  GCV triphosphate 
competes with deoxyguanosine triphosphate (dGTP) to inhibit the HCMV DNA polymerase and 
prevents DNA synthesis.  Incorporation of GCV in place of dGTP into the nascent DNA chain 
causes termination of chain elongation.  Resistance of GCV maps to UL54 (HCMV DNA 
polymerase) and UL97 (protein kinase).  Oral bioavailability of GCV is low (~ 6 %) so the 
prodrug VGCV, the L-valyl ester of GCV, was produced (Figure 2).  VGCV is given orally and 
has an oral bioavailability of ~60% (5).  It targets the same step in HCMV infection as GCV.  
Both GCV and VGCV are used to treat HCMV retinitis, HCMV in AIDS patients, and SOT 
patients.  Newborns born with congenital HCMV have been approved to receive GCV.  Even 
though GCV is considered the gold standard for treatment of HCMV, it has many side effects.  
GCV can lower the number of cells types found in your blood.  One type of cell affected is 
neutrophils.  These are white blood cells and the main component of circulating white blood cells 
and serve as the primary defense against bacterial infections in the blood.  A reduction in 
neutrophils (neutropenia) can lead to bacterial infections in the blood and if untreated can lead to 
serious and life-threatening problems (1).  In animal experiments, GCV has shown to be 
mutagenic, carcinogenic and teratogenic indicating that GCV is very toxic.  Since GCV is a 
teratogen in animals, it is not given to patients who are pregnant or want to become pregnant (74).  
Other side effects are nausea, vomiting, diarrhea, constipation, stomach pain, belching, loss of 
appetite, changes in ability to taste food, dry mouth, mouth sores, unusual dreams, nervousness, 
depression, sweating, flushing, and joint or muscle pain or cramps (56). 
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Figure 2: Current antivirals approved for treating HCMV infections.
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  CDV is a nucleotide analog that inhibits chain elongation by inhibiting incorporation of 
dCTP into the viral genome (32).  CDV (Figure 2) already has the first phosphate, and cellular 
kinases will add two more phosphates to yield the triphosphate form needed to inhibit the viral 
polymerase.  Thus, unlike GCV, CDV does not need the viral kinase UL97 to perform the first 
phosphorylation.  Incorporation of CDV leads to DNA chain termination.  CDV is an acyclic 
nucleoside phosphonate that has activity on a broad spectrum of DNA viruses and is a second 
line of defense against HCMV retinitis.  The major toxicity of CDV is renal toxicity, a particular 
concern in renal transplant patients (33).  CDV binds to a receptor on the convoluted proximal 
tubules and prevents excretion of CDV.  The levels increase in the renal cortex, which can lead 
to kidney failure.  CDV is teratogenic and carcinogenic; therefore, it is not prescribed for 
pregnant women (32, 58, 82).  
Foscarnet (FOS) (Figure 2) is a pyrophosphate analog.  It does not have to be 
phosphorylated by host or viral kinases to be active.  Foscarnet inhibits the viral polymerase by 
binding to the pyrophosphate-binding site in DNA polymerase and hence blocking the release of 
pyrophosphate from the terminal nucleoside triphosphate on the growing DNA chain (32).  
Direct binding to the pocket prevents dephosphorylation of the terminal nucleoside triphosphate 
causing chain termination.  Resistance mutations map to the viral polymerase gene (UL54) (72).  
This antiviral is used in patients that fail GCV therapy or cannot be treated with GCV because of 
adverse side affects.  FOS is used for the treatment of HCMV retinitis but has a severe effect on 
renal function.  FOS causes mineral and electrolyte abnormalities that stem from the renal 
impairment (144).  It is considered a second line therapy and is used to rescue patients that failed 
GCV treatment (111).  Due to the adverse side affects, this antiviral is considered a teratogen and 
is not approved for use in pregnant women (36). 
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Fomivirsen (Figure 2) is a 21 nucleotide antisense RNA.  The sequence is complementary 
to the mRNA sequence of the HCMV immediate-early-2 gene (IE2).  It is used to treat HCMV 
retinitis and is directly injected into the eye (101).  Fomivirsen was the first siRNA to be 
approved by the FDA for treatment of a human disease in 1998.  The treatment consists of 
injections into the eye every 2 weeks (2 injections) followed by maintenance injections once 
every four weeks.  The major disadvantage is inflammation in the eye, which is treated by topical 
corticosteroids.  Fomivirsen is a second line antiviral that is only given to AIDS patients with 
HCMV retinitis (7). 
Currently, there is no approved method for treating a primary infection during pregnancy.  
HCMV can be treated prophylactically with intravenous immunoglobulin.  Hyperimmune 
Human CMV immune globulin (HCMV-IG) is IgG pooled purified blood (plasma) from 
individuals that have high titer HCMV antibodies.  The antibodies supplied by HCMV-IG can 
help to fight an infection from HCMV and is routinely used in SOT patients (35).  HCMV-IG is 
not a teratogen and so is deemed safe for use in pregnancy.  Evidence has shown about 50% 
prevention of HCMV disease in SOT patients.  Nigro et al. (93) found that HCMV-IG is safe for 
the treatment of pregnant women and showed evidence of efficacy for both treatment and 
treatment of congenital infections.  In the US, HCMV-IG is available for patients receiving 
kidneys, liver and heart transplants when the recipient is seronegative.  Bone marrow transplant 
patients are given HCMV-IG in combination with approved antivirals such as GCV (102).  
HCMV-IG is FDA approved for patients undergoing kidney, lung, liver, or heart transplants, but 
is not yet approved for pregnant women (141).  
Viruses that are resistant to GCV, CDV, and FOS often have mutations in the DNA 
polymerase as all three drugs target the viral DNA polymerase.  Multidrug cross-resistance can 
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occur, meaning that if GCV resistance occurs changing to CDV may not be effective because of 
the resistance mutations.  Moreover, each drug is associated with significant toxicities and 
therefore is suboptimal for treating pregnant women.  Currently, there is no FDA approved 
antiviral to treat pregnant women who become infected with HCMV. 
Virion structure 
The HCMV virion has a diameter of 200 to 300 nm (Figure 3).  Within the interior is a 
nucleocapsid with T=16 icosahedral symmetry about 125 nm in diameter (86).  The capsid is 
made up of 150 hexamers and 12 pentamers (6), for a total of 162 capsomers.  The capsid is 
composed of five core proteins: (1) major capsid protein  (MCP, UL86) comprising the hexamers 
and pentamers; (2) minor capsid protein (UL46); (3) minor capsid protein binding protein 
(UL85), which combines with UL46 to form triplexes; (4) smallest capsid protein (SCP, UL48-
49) found on the tips of MCP; and (5) the portal (UL104), which is a specialized pentamer that 
forms an opening for DNA to enter the capsid.  The portal is a ring-like dodecameric complex 
located at one of the twelve vertices.  The capsid is formed in the nucleus where the proteins 
autocatalytically assemble around a scaffold (UL80.5). Surrounding the capsid is the tegument, 
which is comprised of 27 proteins; many of which are phosphorylated.  The most abundant 
tegument protein is phosphoprotein 65 (pp65), which is derived from the UL83 gene (26).  The 
tegument is contained within a host cell-derived lipid bilayer.  Embedded in the surface of the 
bilayer are three separate viral glycoprotein complexes: glycoprotein B (gB), glycoprotein 
H:glycoprotein L (gH:gL), and glycoprotein M:glycoprotein N (gM:gN) that function in viral 
entry.  gB is the major envelope glycoprotein that mediates viral entry.  An alternative complex 
of gH:gL with proteins UL128, UL130, and UL131 (gH/gL/UL128-131) aids in efficient entry 
into epithelial and endothelial cells (see Appendix A).  
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Figure 3:  HCMV Virion. 
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Commonly used laboratory strains, such as Toledo, Towne, and AD169, are fibroblast-
adapted and have acquired mutations in the genes UL128, UL130 or UL131 that prevent 
formation of this complex.  Consequently, these strains do not efficiently infect endothelial and 
epithelial cells.  Because these complexes contain neutralizing epitopes, they are targets for 
vaccine development. 
Viral genome structure 
 
The genome structures of herpesviruses are often complex due to the presence and 
arrangement of direct and inverted repeats; the latter cause large segments to invert.  Herpesvirus 
genomes are categorized into six classes designated A-F (116), (Figure 4).  Class F genomes are 
the simplest, lacking any repeated terminal sequences.  An example of a class F genome is 
Tupaia herpes virus, a virus of tree shrews.  Class A genomes have direct repeats at the genome 
ends.  An example is HHV-6.  Class B genomes have direct terminal repeats that are repeated 
many times and can vary in number between viruses in the same species.  An example is squirrel 
monkey herpes virus (SaHV-2).  An example of a class C genome is EBV, the cause of 
mononucleosis in humans.  In the EBV genome, direct terminal repeats are smaller than the 
previous two examples but within the genome are other directly repeated and unrelated 
sequences that are less than 100-bp.  These sequences subdivide the genome into four unique 
regions.  VZV has a class D genome and is the cause of chicken pox and shingles humans.  The 
VZV genome has two unique regions: unique long (UL) and unique short (US).  As shown in 
Figure 4, US is flanked by an internal inverted repeat (IR) and a terminal inverted repeat (TR), 
which allow the US region to invert in relation to UL.  This genome forms two equal molar 
isomers. 
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Figure 4:  Genome Structures of Herpesviruses.  There are six classes of genomes A-F in 
Herpesviruses.  Class A genomes contain a left terminal repeat (LTR) and a right terminal repeat 
(RTR) and forms 1 isomer.  Class B genomes contain direct terminal repeats, repeated many 
times designated by the vertical lines and forms one isomer.  Class C genomes have smaller 
direct terminal repeats (vertical lines) and contain internal repeats designated as R1 to R4.  Class 
C only forms one isomer.  Class D contains an internal repeat (IR) and a terminal repeat (TR) in 
inverted orientation separating unique long (UL) and unique short (US) sequences forming 2 
isomers.  Class E genomes on the left end contain a sequences repeated n times next to b 
sequences flanking the UL region.  These are inverted orientation as denoted by the slanted hash 
marks.  The right end contains a sequences next to inverted c sequences (denoted by slanted hash 
marks) flanking the US region.  This configuration forms 4 isomers.  Terminal repeats have not 
been described for Class F genomes.  Adapted from Fields 5th edition (39). 
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The class E genomes of HCMV and HSV-1 are the most complex, comprised of long (L) and 
short (S) segments that are delineated by large inverted repeats: L segments are bordered by 
inverted b sequence repeats and S segments are bordered by inverted c sequence repeats 
(116)(Figure 5-A).  Where the L and S segments meet is called the L/S junction (Figure 5-A), 
which is comprised of bʹ′ sequence and cʹ′ sequence repeats flanking an aʹ′ sequence repeat.  This 
creates the bʹ′aʹ′cʹ′ internal L/S junction.  The genome ends also contain a sequences.  The number 
of a sequences can be variable, containing one to several sequences denoted by the n in Figure 5.  
The inversion of both UL and US regions allows the genome to by form four isomers.  L/S 
junctions found within genomes are identical to junctions formed by genome circularization.  
Hence, S and L segments within concatemers are all delineated by identical L/S junctions.  The a 
and aʹ′ sequences located at genomic termini and within each L/S junction contain cis elements 
that direct terminase where to cleave the viral DNA.  
The HCMV genome is shown in detail in Figure 5-A.  There are two types of genomes in 
the laboratory adapted strain AD169: type 1, which has no a sequence at the right end; and type 
2, which has at least one a sequence at the right end.  Guinea pig CMV (GPCMV) is one of the 
models for HCMV.  The GPCMV genome structure does not have inverted repeats within the 
genome, but it does have direct terminal repeats (Figure 5-B).  Like HCMV, GPCMV has two 
types of genomes: type 1 with no terminal repeat on the right end; and type 2, which has one 
terminal repeat on the right end.  HCMV can form four isomers as shown in Figure 6.  UL is 
flanked by inverted b sequences that allow UL to flip orientation, while US is flanked by inverted 
c sequences, that similarly allow US to flip (65, 76, 81).  The numbers below the hatched boxes  
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Figure 5:  Genome Structure of Cytomegalovirus.  (A) HCMV genome structure showing 
major features.  Type 1 contains one a sequence on the right end.  Type 2 has at least one a 
sequence.  (B) Guinea pig CMV genome structure, type 1 has only the terminal repeat left (TRL) 
and type 2 contains TRL and terminal repeat right (TRR). 
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indicate orientation of the region.  For the P structure, the numbers are read from left to right 
1\2\3\4.   
When the UL region has changed its orientation to form the inverted L (IL) isomer, the 
numbers read 2\1\3\4.  The two other isomers that can form are inverted short (IS) and inverted 
long inverted short (ILS).  IS is numbered 1\2\4\3 and ILS is 2\1\4\3.  Each isomer is found in 
equimolar quantities.  Subsequently one isomer is not preferred over another.  This aspect of the 
virus enhances the complexity in interpretation of data. 
 HCMV replication, packaging and cleavage 
Once HCMV enters a cell, the capsid makes its way to the nuclear envelope via 
microtubules.  The capsid docks to a nuclear pore and the DNA is extruded out of the capsid, 
through the nuclear pore and into the nucleus of the host cell.  Peng et al. (100) used a closely 
related virus, murine gamma herpesvirus 68 (MHV-68), to describe the life cycle of MHV-68 in 
host cells by electron tomography displaying a three dimensional representation of viral entry 
into the nucleus, DNA entering the capsid and the capsid leaving the nuclear membrane (100).  
In the nucleus, the DNA circularizes and begins replication.  The current model for HCMV DNA 
packaging and cleavage is shown in Figure 7.  The following sections refer to this model. 
Concatemer synthesis 
DNA synthesis in herpesviruses begins after the genome enters the nucleus.  The linear 
dsDNA genome circularizes and replicates producing large concatemers of dsDNA linked in a 
head-to-tail fashion.  The concatemers are thought to be more complex than simple linear 
molecules (130).  Complete digestion with restriction enzymes that cut once per genome 
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Figure 6:  HCMV Genome Isomerization.  The prototype shows the major segments of the 
HCMV genome.  Red denotes the long (L) segment and blue denotes the short (S) segment.  The 
yellow bar denotes a sequences, terminal a sequences are not shown for simplification.  The 
smaller slanted lines denote b sequences and the larger slanted lines denote c sequences, both are 
in inverted orientation to each other.  By reading the numbers left to right, the sequence of the 
numbers represents inversion of each segment to form each of the 4 isomers. 
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fails to render a large proportion of replicative intermediate DNA competent to migrate into 
pulsed-field gels.  This suggests that the concatemers contain frequent branches.  Branching 
could occur by homologous recombination and strand invasion priming of DNA synthesis 
similar to the replication mechanism of bacteriophage T4 (88). 
Initial cleavage 
In bacteriophage, it has been proposed that a "terminase" enzymatic complex prepares the 
concatemer by an initial cleavage such that the concatemer end is suitable for translocation into a 
procapsid.  Bacteriophage λ terminase is composed of two subunits, a large ~80 kDa protein and 
a small ~30 kDa protein.  The terminase of HSV-1 is believed to contain pUL15 (~80 kDa), 
pUL28 (~95 kDa) and pUL33 (~19 kDa) (114).  UL15 and UL28 null mutants produce 
concatemeric DNA and assemble capsids but fail to cleave genomic DNA from concatemers or 
to form capsids containing DNA.  Mutations in UL28 that do not allow UL33 to bind to UL28 
show defective cleavage of DNA concatemers (57) suggesting that UL33 affects concatemer 
cleavage.   
HCMV terminase genes are UL89 (homology of HSV-1, UL15), UL56 (homology of 
HSV-1, UL28)(129) and UL51 (homology of HSV-1, UL33) (see Appendix A).   
Docking 
In phage λ, docking to the procapsid is thought to be facilitated by the terminase, which 
remains bound to the end of the concatemer after cleavage (16, 119).  Prior to docking, the 
procapsid is formed in the nucleus.  Capsid proteins assemble around a scaffolding core to form 
a porous procapsid.  In HSV-1, there is a unique portal vertex containing a twelve-subunit ring-
like structure formed from UL6 (92).  The HCMV homolog is UL104. 
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Figure 7:  Herpesvirus DNA packaging.  HCMV protein designations are given with HSV-1 
homologs in parenthesis (courtesy of Michael McVoy). 
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DNA Translocation   
Driven by the terminase, concatemeric DNA is believed to transit through the portal to 
enter the procapsid.  DNA translocation requires energy from hydrolysis of ATP.  In phage λ, 
ATPase activities have been found in both the small and large subunits.  An ATP-binding motif 
is found in HSV-1 UL15 and a point mutation in this motif renders the protein unable to 
complement a UL15 null mutant, indicating that the ATP-binding motif is critical for HSV-1 
terminase function (160).  In HCMV, a crystal structure of the C-terminal end of UL89 has been 
determined.  This part of the protein is believed to contain the nuclease activity (90).  The N-
terminal end of UL89 contains a predicted ATPase domain that is thought to be important for 
DNA translocation (17). 
Scaffold removal and morphological maturation 
 As DNA is translocated into the procapsid, the scaffold is prototypically cleaved and the 
fragments exit the capsid.  The procapsid morphologically matures into a more closed and 
angular icosahedral structure.  Three types of capsids can be formed: A-capsids are empty and 
are believed to be formed by the spontaneous loss of DNA; B-capsids contain proteolytically 
cleaved scaffold and are thought to form by spontaneous proteolysis without DNA packaging; C-
capsids are the mature form that contain viral DNA (Figure 8). 
Terminal Cleavage 
Terminal cleavage is believed to occur at the end of translocation when a head-full of 
DNA (a little less than 235-kb) has entered the capsid.  As the head-full requirement is met, the 
terminase becomes "authorized" to cleave at the next proper cleavage site that it encounters.  
Cleavage sites are defined by specific cis sequences, in HCMV located within the a sequence 
repeats (65, 79).   
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Capsid Stabilization 
The capsid must be sealed or stabilized to prevent premature release of the DNA.  The 
putative sealing protein in HCMV is UL77.  The homolog in HSV-1 is UL25.  UL25 was located 
on the vertices of C capsids by immunogold EM analysis (23).  This implies that UL25 is on the 
outer surface of the capsid and not internal since it could be captured by antibody.  In HSV-1, it 
has been suggested that UL25 has many roles in packaging, (i) in stabilization of the capsid, to 
help retain DNA inside the capsid; (ii) may be a trigger to nuclear egress; (iii) used as an anchor 
for tegument proteins; (iv) play a role in uncoating of the incoming viral genome (75, 91, 105, 
133).  UL25 binds to UL17, which has been shown to bind to the portal.  In a null UL17 mutant, 
less UL25 is found in the capsid (138), suggesting that UL17 is involved at an earlier step in 
packaging and UL25 binds UL17 at a later point before nuclear egress.  Once the capsid is 
stabilized by UL25, nuclear tegument proteins are acquired and the capsid is ready for egress out 
of the nucleus. 
Halogenated Benzimidazoles 
The halogenated benzimidazoles were created in the laboratories of Leroy Townsend and 
John Drach (140).  These compounds are nucleoside analogs but they do not act at the stage of 
viral DNA synthesis.  They act at a later point in infection during packaging and cleavage of the 
viral genome but before the capsids leave the nucleus (143).  Packaging and cleavage are good 
antiviral targets since this process is important only for the virus and not for the host cell.   
2-bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole (BDCRB) and 2,5,6-trichloro-
1-(β-D-ribofuranosyl) benzimidazole (TCRB) are derived from 5,6-dichloro-1-(beta-D-
ribofuranosyl)benzimidazole (DRB) (Figure 9) and originally synthesized by Townsend et al.  
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Figure 8:  A-B-C- Capsids.  A-capsids appear empty since they do not contain scaffolding or 
DNA.  B-capsids look like a bicycle wheel, which still contains the scaffolding.  C-capsids 
contain genomes, which appear as a dark center.  Transmission Electron Micrograph, 10,000X. 
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(140).  Both compounds block formation of unit HCMV genomes from concatemeric DNA (68, 
143).  Resistance to BDCRB was mapped to UL89 and resistance to TCRB was mapped to UL89 
and UL56 (68, 143).  UL89 and UL56 are subunits of the terminase.   
These compounds were not pursued for further development because in vivo both 
BDCRB and TCRB were processed to a less active form while also creating cytotoxic aglycones 
(created when the sugar moiety is cleaved from the glycoside) (20).  BDCRB and TCRB are both 
D-isomers, referring to their spatial orientation.  In Figure 9, the difference between TCRB and 
BDCRB is the chlorine at position 2 in TCRB has been replaced with a bromine in BDCRB.  
BDCRB is degraded very quickly in the body into an inactive form (20).  To prevent rapid 
degradation, a common technique is to change the configuration from the D-isomer to the L-
isomer.  The D- and L- are referring to isomerized form of the sugar (ribose) of the nucleoside.  
If this strategy does not work then amino acids may be added to the sugar moiety.  These 
techniques are ways to manufacture compounds that can escape enzyme degradation.  To 
circumvent instability problems, efforts were made to stabilize BDCRB.  Two classes of 
compounds came from these efforts.  The first class is a L-sugar analog of BDCRB called 
Maribavir (1263W94) (Figure 9).  Maribavir is active against HCMV and EBV (34, 154).  This 
agent modestly inhibits DNA synthesis (8) and nuclear egress (67, 155) by inhibiting activity of 
HCMV kinase UL97 but curiously does not significantly impair DNA packaging.  Mutations that 
confer resistance have been found in UL97 and UL27 (19, 72).  Maribavir has gone through two 
Phase I single-dose dose-escalation clinical trials.  No major safety concerns were found, but 
some volunteers reported headaches and loss of taste (34, 69, 150).  Maribavir has also 
concluded a phase I randomized dose-escalation study in HIV-1-infected males with  
 
 
29 
 
 
Figure 9:  Inhibitors of viral DNA packaging. 
 
 
30 
 asymptomatic HCMV; the drug was active in reducing viral load in semen in the doses used 
(150).   
The next step was a phase II multicenter, randomized, double-blind, placebo-controlled, 
dose-ranging study over a 12 week period.  The group studied was SOT patients.  Using 
preemptive therapy, patients that received Maribavir, none reported HCMV disease while three 
cases were reported with the placebo.  This study (154) suggested clinical efficacy was shown in 
decreased viral shedding and prevention of reactivation in stem cell transplants (72, 154).  In 
phase III trials to evaluate prophylactic use, Maribavir failed to significantly reduce HCMV 
disease and the trial was stopped (34).  The fate of Maribavir is unknown at this time. 
The second compound is the D-sugar analog GW275175X (Figure 9) (142).  The 
difference between BDCRB and GW275175X is the pyran configuration (1 oxygen and 5 carbon 
ring) of GW275175X in place of the furan configuration (1 oxygen and 4 carbon ring) of 
BDCRB (142).  The mode of action of GW275175X appears similar to the parent compound 
BDCRB, that is, it is a maturational inhibitor.  It has completed Phase I trials in healthy 
individuals and has an in vitro activity equal to or greater than GCV.  With its unique mechanism 
of action, this compound is a good candidate to move forward in clinical development (142).  
Currently, this antiviral candidate has not moved forward due to the advancement of Maribavir. 
The phenylenediamine sulfonamide BAY 38-4766 inhibits packaging and cleavage much 
like BDCRB and TCRB, but as Figure 9 shows, the structure is not configured as a nucleoside 
analog, but targets the same component, packaging and cleavage, as BDCRB and TCRB.  BAY 
38-4766 has been tested in mice and guinea pigs with favorable results.  This compound crosses 
the placenta in the guinea pig model (127) making it attractive for possible use in pregnant 
women.  Mutations that confer resistance map to UL89 and UL56 (15), these are the same targets 
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as BDCRB and TCRB.  Initial clinical trials showed the compound safe in single oral doses in 
healthy males, but further clinical development has been discontinued for undisclosed reasons 
(7). 
AIC246 (AiCuris GmbH & Co KGin Wuppertal, Germany) is a new class of HCMV 
maturational inhibitors that is currently undergoing clinical trials.  It acts on the viral terminase 
and is not expected to have cross-resistance with currently approved antivirals.  Phase I trials 
have been completed and indicate that the compound is safe and well tolerated.  According to 
AiCuris’s website [http://www.aicuris.com/index.php/fuseaction/download/lrn_file/20101021-
press-release-hcmv-eind-e.pdf], AIC246 has undergone a Phase IIa trial showing good activity 
against multi-resistant HCMV.  This drug was administered as pre-emptive treatment meaning 
that no disease was currently present, but HCMV could occur at a later time point as with SOT 
patients (4).  Currently, the compound is undergoing a Phase IIb trial where testing is being done 
on stem cell recipients who are at a greater risk of developing HCMV disease.  AIC246 is being 
given prophylactically after transplant.  At this time, AIC246 is showing promise as a novel 
candidate antiviral (71). 
BDCRB, TCRB, GW275175X, and BAY 38-4766 inhibit HCMV at the step of DNA 
cleavage and packaging.  One of the properties of all of these compounds is the formation of a 
supergenomic species called monomer-plus.  However, the mechanism of action of such 
"maturational" inhibitors remains unclear.  In HCMV, concatemeric DNA continues to be 
formed, but in the presence of these drugs, the formation of unit genomes is altered, causing a 
reduction in the amount of 230-kb genomic DNA and an increase in monomer-plus DNA (270-
kb) (143). 
Guinea Pig Cytomegalovirus 
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Guinea pigs are small rodents that have been used as a model system for human 
infectious disease since the 17th century when Italian biologists took sections of guinea pigs to 
study anatomy (48).  Guinea pigs are easy to handle, small, and cost less to maintain than larger 
animals.  The reproductive system of guinea pigs is more like humans than mouse and rat (131).  
Guinea pigs have a gestation period of 59 to 72 days, which can be divided into trimesters that 
correlate to human pregnancy (131).  The hemochorial placenta of the guinea pig is structurally 
similar to the human placenta.  Even though guinea pigs cannot be infected with HCMV, guinea 
pigs can be infected with guinea pig cytomegalovirus (GPCMV), which, like HCMV, crosses the 
placenta of the pregnant female, causing congenital infections.  Congenitally infected pups 
display growth retardation, brain damage, and hearing loss, all of which are similar to HCMV 
infection in infants (124). 
The genome structure of GPCMV is shown in Figure 4-B.  The genome length is ~ 233-
kb (128).  The only known GPCMV strain is designated 22122, which was derived from the 
salivary gland of a guinea pig (131).  There are two types of genomes: type 1, which contains 
terminal repeats on both ends; and type 2, which has only one terminal repeat on the left end.  
The GPCMV genome does not invert and therefore there is only one isomer.  The simple 
genome structure helps in simplifies the complexities of packaging and cleavage.  
GPCMV is sensitive to BAY 38-4766 and BDCRB.  BAY 38-4766 has been evaluated in 
vivo in the GP congenital infection model (127).  BDCRB in vitro studies have provided unique 
insights into DNA packaging and mechanism of action of the inhibitors discussed more in 
Chapter 3. 
Rational for research. 
The aims of this project are threefold.  The first aim is to characterize a GPCMV mutant 
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that is resistant to BDCRB (Chapter 3).  As in HCMV, BDCRB targets the terminase complex in 
GPCMV.  Instead of forming a unique species, as in HCMV with the formation of a 
supergenomic species that migrates at 270-kb (143), abundant monomer genomes (230-kb) are 
produced (94).  The resistant virus has a mutation in GP terminase GP89 and the terminal ends 
have been altered.  The terminal ends of the resistant GPCMV appear to be repeated several 
times.  BDCRB resistance in HCMV has not resulted in reiteration of ends, but the GPCMV 
mutant virus did have a large deletion.  Could the reiteration be due to the genome attempting to 
maintain a specific size or play a role in resistance?  Under normal conditions, GPCMV and 
HCMV genomes maintain a constant size.  Various mutated viruses were passaged at least 32 
times to determine if the reiteration would happen without BDCRB.  Chapter 3 examines if 
reiteration occurred to maintain virus genome length or did reiteration occur because of 
resistance to BDCRB.   
A major structural difference between HCMV and GPCMV genomes is the lack of an 
internal junction (L/S junction) in GPCMV (Figure 5).  By removing the internal junction in 
HCMV, the genome becomes structurally similar to GPCMV (Chapter 4).  The virus was viable 
and replicated with titers close to wild type.  This lead to the second aim, is monomer plus DNA 
dependent on the internal junction?  If the internal junction is removed from HCMV, then 
monomer plus will not be produced in the presence of BDCRB.  The model for monomer plus is 
based on the sizes of the long and short segments.  The long segment is ~190-kb in length, while 
the short segment is ~40-kb in length.  Underwood et al. (143) describe in the presence of 
BDCRB a DNA species that migrated on a pulse field gel at ~270-kb.  This is 40-kb longer than 
monomer at 230-kb.  This suggests that in the presence of BDCRB, the proper cleavage site is 
skipped and an additional short arm is added to the genome creating a short-long-short genome, 
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or monomer plus.  The hypothesis is that monomer plus DNA can not be formed in the presence 
of BDCRB without the internal junction present.  Chapter 5 contains my results from exposing 
HB15∆L/S (a virus lacking the internal junction) to BDCRB. 
The third aim begins work in vaccine development.  Currently, there is no vaccine 
available for HCMV.  While vaccine development does not involve antivirals, it is another 
important method to protect people, especially women from contracting an initial HCMV 
infection during pregnancy.  A vaccine would also benefit SOT patients and help to eliminate the 
risk of a seronegative patient contracting HCMV from a seropositive organ.  In Chapter 6, 
Frances Saccoccio and I, co-authored a paper concerning viral entry into several different host 
cell lines.  The goal was to determine if the known viral entry complex of UL128-131 for 
epithelial cells was needed to enter non-cancerous derived cell lines.  This new viral entry 
complex is not found in the wild type strain AD169.  AD169 is pH independent and enters the 
cell by fusion at the cell membrane; BADrUL131-Y4 has a functional UL128-131 complex 
entering the host cell in a pH dependent pathway.  AD169 mutated over the years of the virus 
being passaged in only fibroblasts cells.  Once mutated, AD169 no longer efficiently entered 
epithelial cells.  BADrUL131-Y4 does contain a repaired UL128-131 entry complex.  This virus 
also contains GFP, so the virus can be observed by blue light under a fluorescence microscope.  
By infecting various epithelial cell lines with either BADrUL131-Y4 or HB15-T178b (this also 
contains GFP and represents AD169) viral entry into epithelial and fibroblasts was observed.  
The results from this work are found in Chapter 6.   
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CHAPTER 2: Materials and Methods 
 
Cells 
 
Table 2 summarizes the cell lines used.  MRC-5 (ATCC CCL-171), ARPE-19 (ATCC 
CRL-2302), and HBE4-E6/E7 (ATCC CRL-2078) cells were obtained from ATCC.  The 
immortalized cell lines, HFK-2, Cx, V428, and HTE 21505 (161) were a gift from Aloysius 
Klingelhutz.  ARPE-19 cells were propagated in high glucose Dulbecco’s modified Eagle 
medium (DMEM; Gibco-BRL) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS)(Gibco-Invitrogen), 10,000 IU/L penicillin, 10-mg/L streptomycin sulfate, and 29.2 
mg/mL L-glutamine (Gibco-Invitrogen).  FBS is heat-inactivated by incubating thawed serum at 
52° C for 30 minutes.  MCR-5 cells were propagated in Eagle’s minimum essential medium 
(EMEM) supplemented with 10% heat-inactivated fetal bovine serum, 10,000-units/mL 
penicillin G, 10,000-µg/mL streptomycin sulfate, and 29.2 mg/mL L-glutamine (Gibco-
Invitrogen).  Guinea pig embryo fibroblast (GEF) or lung fibroblast (GLF) cells were propagated 
in EMEM with 10% heat-inactivated fetal bovine serum, 10,000-units/mL penicillin G, 10,000-
µg/mL streptomycin sulfate, and 29.2 mg/mL L-glutamine (Gibco-Invitrogen). 
HFK-2, Cx, V428, and HTE 21505 cells were propagated in keratinocyte serum-free 
medium (KSFM, Gibco 17005042).  HBE4-E6/E7 were propagated with KSFM supplemented 
with 5 ng/ml human recombinant epidermal growth factor (EGF) 1-53 (Invitrogen), and 0.05 
mg/ml bovine pituitary extract (Invitrogen).  HTE 21505 cells were propagated in KSFM  
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Table 2:  Cell Lines. 
 
Cell line  Tissue (cell type) 
GLF fibroblast guinea pig lung  
GEF fibroblast guinea pig embryonic 
MRC-5 fibroblast human fetal lung 
ARPE-19 
epithelial 
human retinal pigment 
epithelium 
HFK-2 human foreskin (keratinocyte) 
Cx human cervix (keratinocyte) 
V428 human vagina 
HTE 21505 human tonsil 
HBE4-E6/E7 human bronchus 
 
 
 
 
 
37 
supplemented with 5 ng/ml human recombinant EGF and 0.05 mg/ml bovine pituitary extract 
with 10-ng/ml cholera toxin (Sigma).  All cell cultures were maintained at 37°C in a 5% CO2 
atmosphere. 
Plasmids 
The following plasmids were used pTD-Tn1721 (a gift from Don Yu) (158), to supply 
kanamycin, pMA228, as shuttle to move kanamycin from pTD-Tn1721 into pGEM-T, and 
pMA236, to make linear kanamycin marker with flanking HCMV homology.  Plasmids used for 
Southern hybridizations are pGP48, pGP21, pON227, pON2333, pON1101, and pHindIII E (a 
gift from Mark Schleiss).  The plasmids used to detect sequences in GPCMV are shown in the 
HindIII restriction map of GPCMV genome (Figure 10).  The left end R fragment (2.7-kb) is 
detected by pGP48 and the right end O (3.8-kb) or M (4.8-kb) fragment is detected by pGP21.  
Plasmids used to detect viral specific sequences in HCMV are pON227, pON1101, and 
pON2333 (Figure 11). 
Recombinant virus construction 
Bacterial artificial chromosomes (BACs) are fabricated vectors based on the fertility (F) 
factor of E. coli (122).  They are high-capacity vectors for DNA that can carry large inserts up to 
300–kb (162).  Advantages for using BACs are numerous, (1) they are low copy number, 
normally 1 to 2 molecules per cell.  The vectors contain parA and parB that ensure accurate 
partitioning of the F factor DNA.  parB is responsible for excluding extraneous F plasmids from 
cells.  The low copy number reduces undesirable recombination events.  BACs are (2) more 
stable than yeast artificial chromosomes (YACs), which can also carry large inserts(151).  BACs 
are (3) easy to manipulate (122).  BACs are circular and can be separated from E. coli by 
straightforward methods, as described below.  Features of a BAC vector include oriS, origin of 
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replication, parA and parB, to control the rate of replication maintaining one to two BACs per 
cell, and a selectable marker gpt, guanine phosphoribosyltransferase, and flanked by two loxP 
sites (151).  The loxP sites with Cre-mediated recombination can remove the BAC vector to 
prevent side effects in the virus (162). 
BAC HB15Tn7∆k was derived from pHB15, an infectious BAC clone of the HCMV strain 
AD169 genome (55), by insertion of a lacZα-mini-attTn7-Kn cassette at the UL18 locus and 
subsequent removal of Kn (49, 149) (see Figure 11 for progression from AD169 (WT) to 
HB15ΔL/S).  BAC HB15∆L/S was constructed from HB15Tn7∆k using linear recombination 
(Figure 13) to substitute Kn for HCMV nucleotides 178,167 to 191,415 (as numbered in 
GenBank accession #X17403 (18)).  A schematic of pMA228 and pMA236 is shown in Figure 
12, the following explains the procedure.  A Kn-lacZ cassette from pYD-Tn1721 (a gift from 
Dong Yu) (158) was PCR amplified using primers pYD1721-F (5ʹ′- 
CGGTCATATCTGTTTCCTGTA) and pYD1721-R (5ʹ′-AGCGGCCGCAGACTACAAGGA 
and ligated into pGEM-T Easy (Promega) to make plasmid pMA228.  Digestion with PacI and 
religation removed lacZα to produce plasmid pMA236.  Primers Forward ΔL/S (5ʹ′-
CAGTTCATGTAAAAGTCGGTCTCGCCGTGTCCGGCCACGAAGAGGCTGCTCGGTCAT
ATCTGTTTCCTGTA) and Reverse ΔL/S (5ʹ′-
TGCGAGGGGATCATTTATGGGGTCACCGCGTTGTTCGCGAAACATGAACTAGCGGCC
GCAGACTACAAGGA) were used to PCR amplify Kn from pMA236 to produce a PCR 
product comprised of Kn flanked by HCMV sequences (underlined).  Linear recombination 
(Figure 13) (149).  Recombinant virus was selected by gpt selection followed by limiting dilution 
purification.  Candidate clones were screened by PCR to identify clones proper insertion of Kn 
(data not shown).  Two clones were further analyzed by XbaI restriction (Figure 21 and Chapter 
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Figure 10:  HindIII map of Guinea Pig CMV.  The GPCMV genome was restricted with 
HindIII and the resulting fragments are labeled above the fragments.  R is the left terminal 
fragment (2.7-kb) that is detected by pGP48.  Both right terminal ends, O (3.8-kb) and M (4.8-
kb) are detected by pGP21.  The probe pHindIII E detects the E fragment (18.1-kb), this was a 
gift from Mark Schleiss.  Relevant restriction sites are shown: h, HindIII; s, SmaI.  Fragment size 
is given in parentheses in kb. 
R N D F H S G T J P Q K A C B E I ULO
MHindIII
h
R (2.7)
s s
pGP21
M (4.8)
O (3.8)
pGP48
HindIIIEp
E (18.1)
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Figure 11: Location of HCMV plasmids.  AD169 is the wild type virus.  A schematic 
displaying a sequence, b sequence and c sequence.  The hashed boxes represent sequences in 
inverted orientation.  HB15, which is derived from AD169, (55) displaying the location of the 
BAC origin.  HB15Tn7Δk (49) was derived from HB15.  The attTn7 site is shown in the long 
segment.  HB15ΔL/S was derived from HB15Tn7Δk.  The location of the probes is shown.  
Fragment size is given in parentheses in kb.  Regions within the BAC are lox P sites, gpt (used as 
a marker for maintaining the BAC ori), parB and parA for partitioning and oriS of F Factor. 
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4) and clone 2 was subsequently designated as HB15∆L/S.   
Virus Reconstitution 
Viruses HB15∆L/S and HB15Tn7∆k were reconstituted by transfection of their 
respective BAC DNAs into MRC-5 cells (51).  MRC-5 cells were plated into six-well dishes 
such that 70-80% confluency was attained the next day.  The cells were washed three times with 
DMEM to remove serum and incubated in DMEM for 30 minutes prior to transfection.  One 
microgram of BAC DNA was added to 10 µl SuperFect transfection agent (Qiagen), adjusted to 
a final volume of 100 µl with DMEM, incubated for 30 minutes at room temperature, and mixed 
with 900 µl DMEM-5% FBS.  The DMEM was removed from the cells and replaced with the 
transfection mixture, 1 mL for each well.  After incubation for 4 hours at 37°C, the transfection 
mixture was removed and the cells were incubated in fresh DMEM-5% FBS for 7 days, split 
once, and cultured until the appearance of virus plaques (typically by day 10 post transfection). 
BADrUL131-Y4 was reconstituted by transfection of BADrUL131-Y4 BAC DNA into 
ARPE-19 cells (29).  HCMV strain BADrUL131-Y4 was derived from a BAC clone of the 
HCMV strain AD169 genome that had been modified in E. coli by Wang and Shenk to (1) 
contain a green fluorescent protein (GFP) reporter cassette to permit efficient detection and 
quantitation of viral infection (145), and (2) to express a functional UL131 protein, which 
permits efficient entry and replication in either ARPE-19 or MRC-5 (146).  BADrUL131-Y4 
was reconstituted by transfection of BAC DNA into ARPE-19 cells.  ARPE-19 cells were plated 
into six-well dishes such that 70-80% confluency was attained the next day.  The cells were 
washed three times with high glucose DMEM to remove serum and incubated in high glucose 
DMEM for 30 minutes prior to transfection.  One microgram of BAC DNA was added 
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Figure 12:  Construction of pMA228 and pMA236.  Using YD-Tn1721 (158) to supply LacZ 
and Kan, PCR primers were designed to duplicate the 2.9-kb region shown.  The PCR product 
was ligated into pGEM-T Easy Vector to create pMA228.  This plasmid was cut with PacI and 
religated to create pMA236.  Creating PCR primers with 50-bp HCMV sequence on the end of 
each primer, formed the linear product containing Kan flanked by HCMV sequence. 
HA myc Res F FGFP LacZ Kan FLAG VSV-­G
2.90  kb
3.66  kb
YD-­Tn1721
pTD-­1721-­F pTD-­1721-­R
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Figure 13:  Linear Recombination of HB15∆L/S.  The linear fragment created had homology 
to the HCMV sequence on either side of the internal junction.  Candidate clones were screened 
by PCR and further confirmed by XbaI restriction. 
Linear  Recombination
Kan
HCMV HCMV
b b ccaa aƍ ƍ ƍattTn7
b ca aattTn7
Kan
HB15Tn7¨k
HB15¨L/S
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 to 10 µl SuperFect transfection agent (Qiagen), adjusted to a final volume of 100 µl with high 
glucose DMEM, incubated for 30 minutes at room temperature, and mixed with 900 µl high 
glucose DMEM -5% FBS.  The high glucose DMEM was removed from the cells and replace 
with the transfection mixture, 1 mL for each well.  After incubation for 4 hours at 37°C, the 
transfection mixture was removed and the cells were incubated in fresh high glucose DMEM -
5% FBS for 7 days, split once, and cultured until the appearance of virus plaques (typically by 
day 10 post transfection).  BADrUL131-Y4 was amplified by passage exclusively in ARPE-19 
cells.  BADrUL131-Y4 supernatants were clarified by centrifugation, adjusted to 0.2 M sucrose, 
aliquoted, and stored at -80°C.  Viral titers of 1 x 105 (BADrUL131-Y4) were determined by 
limiting dilution in 96-well plates using MCR-5 cells.   
HB15-t178b was reconstituted by transfection of HB15-t178b BAC DNA into MRC-5 
cells.  Briefly, 20 µl of JetPEI (Polyplus-transfection SA) was added to 200 µl 150 mM NaCl, 
mixed with 200 µl 150 mM NaCl containing 10 µg of HB15-t178b BAC DNA.  The mixture was 
vortexed for 10 s and allowed to incubate 30 min. at room temperature, then added to one well of 
a 6-well plate containing 70-80% confluent MRC-5 cells in 3 ml DMEM and incubated at 37 °C.  
The medium was changed after 2 days and evidence of viral infection (GFP+ foci and cytopathic 
effect) appeared within 10-14 days. 
Virus and Virus Culture 
Table 3 summarizes the viruses and strains used.  Wild type GPCMV strain 22122 
(ATCC VR-682), R-75, BVD and N2 (28) were propagated in GEF or GLF cells.  The viruses 
are maintained in the appropriate required media used by the cells.  Refer to the pervious section 
on Cells for media and supplements used. 
HB15-t178b retains the strain AD169 mutation that disrupts expression of UL131 and is 
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therefore predicted to enter ARPE-19 cells inefficiently (145).  Virus BADrUL131-Y4 (a gift 
from Thomas Shenk and Dai Wang) (146) was derived from a different BAC clone of the 
HCMV strain AD169 genome (159) that had been modified in E. coli by Wang and Shenk to (1) 
contain a GFP reporter cassette to permit efficient detection and quantitation of viral infection 
(145), and (2) to express a functional UL131 protein, which permits efficient entry and 
replication in either ARPE-19 or MRC-5 cells (29, 146).   
HCMV strain AD169 and bacterial artificial chromosome (BAC)-derived viruses 
HB15Tn7Δk and HB15ΔL/S were propagated in MRC-5 human fetal lung fibroblasts (ATCC 
CCL-171).  Viral stocks of HB15-t178b and BADrUL131-Y4 (147) were prepared from cell 
culture media that was clarified by centrifugation, adjusted to 0.2 M sucrose, aliquoted, stored at 
-80°C, and titered on MRC-5 cells by limiting-dilution in 96-well plates (27).  Limiting-dilution 
is a method used to titrate virus stocks.  Briefly, prepare 96-well plates with confluent cells in 
100 µL media in each well.  Dilute the virus sample 1:10 into 5.0 mL media.  Serially dilute 
virus sample to 10-9.  Beginning with the lowest dilution, pipet 100 µL of sample into 32 wells of 
a pre-labeled 96-well plate.  Plates are read 14 days after infection for virus (+) or no virus (-).  
The Poisson distribution was used to correct for the probability of multiple virus hits per well 
using the equation:  
titer (pfu/ml) = 10 (-ln[(32-x)/32]) f, where f = dilution factor 
Antivirals 
BDCRB and TCRB were a gift from John Drach and Leroy Townsend (University of 
Michigan) (140) and were dissolved in DMSO at a stock concentration of 100 mM.  The 
compounds were stored at -20°C. 
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Table 3:  Virus Stocks 
 
Species Virus name Parental 
Strain 
Reference/Source 
GPCMV 22122 22122 ATCC VR-682,  
(53) 
GPCMV R-75 22122 Chapter 3 
GPCMV N2 22122 (28) 
GPCMV N2cre 22122 (28) 
GPCMV BVD 22122 (28) 
GPCMV BVDcre 22122 (28) 
HCMV AD169 ATCC VR-
538 
(118) 
HCMV HB15Tn7Δk AD169 (51) 
HCMV HB15ΔL/S HB15Tn7Δk Chapter 4,(123) 
HCMV HB15-t178b AD169 Chapter 4,  
(123) 
HCMV BADrUL131-Y4 AD169 (147) 
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Generation of BDCRB-resistant GPCMV 
GPCMV strain 22122 was serially propagated in GLFs in EMEM containing 50 µM 
BDCRB for several passages, followed by passage in GLFs in EMEM several more times in 75 
µM BDCRB.  When efficient replication became evident, the stock was subjected to several 
rounds of limiting-dilution cloning in 96-well culture plates to isolate a clonal virus designated 
R-75.   
CHEF and FIGE Electrophoresis 
Contour-clamped homogeneous electric field (CHEF) electrophoresis was performed on 
a CHEF-DR II from Bio-Rad with a run time of 22 hours, switch time of 50 to 90 seconds at 6 
V/cm, and temperature set at 14°C.  The gel was 1% agarose (BioRad) in 0.5 x TBE (45 mM 
Tris-borate, 1 mM EDTA [ethylenediaminetetraacetic acid pH 8.0]).  Field inversion gel 
electrophoresis (FIGE) was performed using 1% SeaKem in 0.5 x TBE.  Electrophoresis was 
performed for 36 hours at 10°C with a switch ramp time for 5 to 60 seconds at 6 V/cm and 
forward to reverse ratio of 3:1.  To prepare DNA sample plugs, cells were washed in PBS 
(phosphate-buffered saline, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) with 
0.5 mM EDTA pH 8.0, scraped from a T-75 cm2 flask, washed with 5 ml cold PBS, and pelleted 
by centrifugation at 2100 rpm at 4°C.  Pelleted cells were suspended in 1% Seaplaque in 0.5 x 
TBE (76), cast into molds, and cooled on ice for 15 minutes.  Plugs were incubated in 1% 
sarkosyl in 0.5 M EDTA and 1mg/ml proteinase K at 52°C for 48 hours, dialyzed 3x in TE 
(10mM Tris, 1 mM EDTA [pH 8.0]) for two hours at 4°C.  Plugs were stored at 4°C in TE.  To 
obtain virion plugs, culture supernatants were centrifuged at 35,000 rpm for 45 minutes at 4°C.  
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The supernatant is decanted and the virion pellet was suspended in 1% Seaplague in 0.5 x TBE, 
cast into molds, and cooled on ice for 15 minutes.  Virion pellets were processed in the same 
manner as cell pellets (above). 
DNA preparation and Southern hybridization 
Maxi-prep BAC DNAs were prepared using the Nucleobond BAC DNA purification kit 
(ClonTech) from 500 mL overnight E. coli cultures grown in LB with 20 µg/mL 
chloramphenicol and redisolved in 100 µl H2O (27).  Virion DNAs were made by low MOI 
infection of confluent MRC-5 cultures and incubation until full cytopathic effect was reached.  
The culture media was clarified twice by centrifugation at 2100 rpm for ten minutes.  The virions 
from the clarified supernatant were pelleted at 25,000 rpm for 45 minutes at 4°C.  Virion DNA 
was phenol/chloroform extracted from the pellets and ethanol precipitated (76, 78).  BAC or 
virion DNA samples were digested with restriction enzymes overnight at 37ºC, 
electrophoretically separated on 0.7% agarose in 0.5x TBE, and visualized by ethidium bromide 
staining and UV light.  Separated fragments were transferred to Nytran nylon membranes 
(Schleicher & Schuell), UV cross-linked (0.12 J/cm2) and hybridized using [32]P-labeled probes 
derived from plasmids pGP48, pGP21, pON227, pON2333, or pON1101 (76, 80).  
Concatemeric DNAs were prepared by embedding infected cells in agarose plugs, 
subjecting the plugs to field-inversion gel electrophoresis to remove monomer DNA, and 
extracting the concatemeric DNA that remained in the plugs (76, 78, 94).  Virion or 
concatemeric DNAs were digested with restriction enzymes and the fragments were separated by 
agarose gel electrophoresis, transferred to Nytran nylon membranes (Schleicher & Schuell), and 
hybridized using isotopically labeled probes (76, 78).  The following probe DNAs were used: R 
probe, a gel-purified MluI/ClaI fragment from pGP48 (78); O probe, HindIII-digested pGP21 
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(78); and E probe, HindIII-digested plasmid pHindIII E, which contains the entire GPCMV 
HindIII E fragment (44) (a gift from Mark Schleiss).   
Sequencing 
Extracellular virion DNAs were subjected to PCR amplification using Easy-A DNA 
polymerase (Stratagene) according to the manufacturer's instructions.  Following purification 
using the QiaQuick or MinElute PCR purification kits (Qiagen), PCR products were either 
sequenced directly or cloned into plasmids using T/A cloning (Promega) or TOPO XL 
(Invitrogen) PCR cloning kits.  Sanger chain termination sequencing of either plasmid-cloned or 
PCR-generated DNA templates was conducted by either the Biopolymer Laboratory at the 
University of Maryland at Baltimore or the Nucleic Acids Research Facility at Virginia 
Commonwealth University.  
Viral entry assays 
Virus stocks were titered using MCR-5 fibroblast cells.  Equal amounts to yield the same 
MOI of HB15-t178b and BADrUL131-Y4 were used to infect replicate cultures of confluent 
cells prepared in 24-well plates.  After 24 hours, cultures were washed three times with PBS and 
fresh medium was added.  Entry efficiency was assessed by the number of GFP+ (infected) cells 
and documented with photomicrographs taken on days 3, 5, and 9 post infection (pi) or on days 3, 
7, and 15 pi using an Olympus LX70 Inverted UV microscope. 
Antibody Neutralization 
Rabbit anti-peptide sera raised against peptides DQYLESVKKIHKRLDVC (from 
UL128), SWSTLTANQNPSPPWSKLTYC (from UL130), and SDFRRQNRRGGTNKRTTC 
(from UL131) were a gift from David Johnson and Brent Ryckman.  The peptides were 
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synthesized by PeptidoGenics (Berkley, CA) and coupled to keyhole limpet hemocyanin (KLH).  
New Zealand White rabbits were immunized with one dose of KLH-conjugated peptides mixed 
with Freund's adjuvant, boosted with KLH-conjugated peptides in TiterMax Gold adjuvant 
(Sigma, St. Louis, MO) (121).  Neutralizing activities were determined by preparing 1:10 
dilutions of each serum followed by additional 2-fold serial dilutions in ARPE-19 culture 
medium.  Each dilution was mixed with an equal volume of ARPE-19 culture medium 
containing 500 pfu of BADrUL131-Y4, incubated for 1 hour at 37 °C, and added to the wells of 
384-well plates containing confluent ARPE-19 monolayers.  Each serum was assayed in 
triplicate and representative photomicrographs were taken using a Nikon Eclipse TS100 inverted 
UV microscope at 5 days post infection.  To evaluate neutralization of viral entry into mucosal 
epithelial cells rabbit anti-peptide sera were used at a 1:20 dilution in media appropriate for each 
cell type.  Each diluted antibody was combined with an equal volume of diluted BADrUL131-
Y4 virus (2500 pfu/ml) and incubated for 1 hour at 37 °C.  The mixtures were transferred to 
wells of 96-well plates containing confluent monolayers of each cell type.  Photomicrographs 
were taken daily for seven days using a Nikon Eclipse TS100 inverted microscope. 
Viral growth curves 
Frozen viral stocks were titered by limiting-dilution in 96-well plates (29).  Confluent 
MRC-5 cells in 75 cm2 flasks were infected with each HCMV virus at an MOI of 4 for single-
step and 0.01 for multi-step growth curves.  Cultures were washed with PBS 3.5 h post infection 
to remove unattached virus and fresh media was applied.  Samples of culture media were 
removed daily for 18 days for single-step or every-other day for multi-step growth curves and 
titered by limiting-dilution as described above.   
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Approximately 106 cells were infected with wild type GPCMV or R-75 at an MOI of 0.01.  
Samples of the supernatants of each flask were removed 3, 5, and 7 days after infection and 10-
fold serially diluted.  Each dilution was used to infect 32 replicate cultures of confluent GLFs in 
96-well plates.  After 14 days, the wells were scored visually for viral infection by formation of 
cytopathic effect.  Titers were calculated by assigning x as the number of positive wells out of 32 
from the highest dilutions that contained positive wells.  The Poisson distribution was used to 
correct for the probability of multiple virus hits per well using the equation: 
titer (pfu/ml) = 10 (-ln[(32-x)/32]) f, where f = dilution factor 
Nuclease Protection Assay 
MRC5’s were infected with 3 ml AD169 to provide an MOI of 0.01.  Cells were 
incubated with virus for 3.5 h and washed in 5 ml of EMEM.  The cultures were divided into 
four groups.  Group 1 was cultured for 3 days with 20 µM BDCRB.  Group 2 was cultured for 7 
days with no BDCRB.  Group 3 was cultured for 3 days in 20 µM BDCRB, next BDCRB was 
removed and replaced with media either containing 20 µM BDCRB or without BDCRB.  Group 
3 was cultured for 4 more days.  Cells were scraped from dishes, rinsed with PBS (no EDTA), 
placed on ice, and pelleted by centrifugation (2000 rpm for 10 minutes) at 4°C.  Cell pellets were 
resuspended in 450 µl ice-cold hypotonic buffer (10mM Tris pH 8.0, 12 mM KCl) and incubated 
on ice for 1 hour, and manually homogenized and split into two equal aliquots.  One aliquot was 
mixed with 4.4 µl 100mM CaCl2, 20.2 µl 10X Nuclease buffer (600mM KCl, 150 mM NaCl, 
200mM Tris pH 7.8) and 6.0 µl Staphylococcal nuclease (Roche, nuclease S7, 15,000 U, 150 
U/µl in reconstitution buffer [50mM Tris pH 7.8, 10mM NaCl, 10mM EDTA, 500µM DTT 
0.1 % NP4O and 50% glycerol]) and incubated at room temperature for 4 hours.  Nuclease was 
inactivated by addition of 9 µl 0.5 M EDTA.  The other aliquot was mixed with 4.4 µl 100 mM 
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CaCl2, 20.2 µl 10X nuclease buffer, and 9 µl 0.5 M EDTA and incubated on ice for 4 hours.  
Treated homogenates were again divided into equal aliquots.  One was processed for TEM, and 
the other embedded in agarose plugs for FIGE/CHEF. 
Transmission Electron Microscopy (TEM) 
Whole cells or cell homogenates were resuspended in 2% glutaraldehyde in 0.1 M 
sodium cacodylate buffer and processed for TEM by the VCU Department of Anatomy and 
Neurobiology Microscopy Facility.  Samples were embedded in molds and sectioned on a Leica 
EM UC6i Utramicrotome (Leica Microsystems).  Sections were examined on a JEOL JEM-1230 
TEM (JEOL USA, Inc.) electron microscope with the Gatan Ultrascan 4000 digital camera 
(Gatan Inc., Pleasanton, CA).  Microscopy was performed at the VCU Department of Anatomy 
and Neurobiology Microscopy Facility. 
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CHAPTER 3:  A Guinea Pig Cytomegalovirus Resistant to the DNA 
Maturation Inhibitor BDCRB 
 
Background 
 The inadequacies of existing HCMV drugs have prompted a search for new anti-virals 
that target processes other than DNA synthesis.  Like other herpesviruses, the genome of HCMV 
is a large (~235-kb), linear, double-stranded DNA molecule.  DNA replication is not well 
understood, but is known to result in formation of complex multimeric replicative intermediates 
composed of genomes linked together in a concatemeric arrangement.  “DNA maturation” is the 
process by which this concatemeric DNA is packaged into capsids and cleaved to form 
encapsidated, mature genomes (14).  As these events are critical for completion of the viral life 
cycle, yet of no importance to host cell metabolism, DNA maturation is an attractive target for 
antiviral interventions.   
 The halogenated benzimidazole BDCRB was the first compound shown to target 
herpesvirus DNA maturation (143).  It does not affect the synthesis of HCMV concatemeric 
DNA, but acts by blocking formation of monomeric genomes from concatemeric DNA (143).  
Similar activities have since been reported for the related compounds TCRB (68) and GW-
275175X (142), and a structurally distinct sulfonamide, BAY38-4766 (15).  GW-275175X and 
BAY38-4766 are potential candidates for clinical development (38), whereas BDCRB and 
TCRB serve as valuable tools to probe the molecular mechanisms of DNA 
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maturation in vitro.  Each of these drugs is believed to target the viral terminase, an enzymatic 
complex that processively packages concatemeric viral DNA into capsids and cleaves the DNA 
appropriately upon encountering specific cis-acting cleavage site sequences (11).  The HCMV 
terminase is comprised of three subunits, UL51, UL56 and UL89.  Amino acid changes in UL56 
and UL89 confer resistance to BDCRB and TCRB, and remarkably, a nearby amino acid change 
in UL89 is associated with resistance to BAY38-4766 (Figure 14).  This suggests that the 
halogenated benzimidazoles and the structurally distinct BAY38-4766 may interact within the 
same region of UL89.   
 As shown in Figure 14, Champier et al.(17) found by sequence analysis twelve conserved 
domains.  Of the twelve domains, only domain V contains the resistance mutations for HCMV 
while domain VI contains the approximate location of the mutation in GPCMV R-75.  
Conserved domain V is 80-residues long (A290 to H370) and contains 31 perfectly conserved 
amino acids.  This region contains a 17-residue highly conserved domain that includes a Walker 
B motif (17).  This motif was found in T4 gp17 and HSV-1 UL15 (85).  The BDCRB mutation 
D344E is not a conserved residue and the TCRB mutation A355T is conserved in human 
herpesviruses except HHV-6 and HHV-7.  Neither of these residues has a homologue in T4 gp17 
(part of bacteriophage T4’s terminase complex) (143).  Conserved region VI is 36-residues and 
contains ten amino acids that are perfectly conserved.  This region has homology with gp17 
region containing portal binding site I (17).  Region VI contains two motifs that resemble a 
putative CCCX metal-binding site.  The R-75 mutation L409P is not located within any 
conserved area but is near HCMV UL89 412FMDE415, which contains features of a portal binding 
motif found in T4 gp17, phage λ and phage T3 (87, 157). 
 
 
55 
 
Figure 14:  HCMV UL89 protein has 12 conserved domains.  Using sequence analysis, 
Champier et al. (17)located 12 conserved regions.  The black boxes at the beginning and towards 
the end represent NLS regions (nuclear localization signals).  Mutations conferring resistance are 
located in regions V and VI.  BDCRB/TCRB are shown in red (D344E, S345A, and A355T).  
Mutations conferring resistance to BAY 38-4766 are shown in purple (D358N, M360I for 
murine CMV, and M357V for GPCMV).  R-75 BDCRB resistance mutation is shown in green 
(L409P). 
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 The complex structure of the HCMV genome often complicates the analysis of viral 
DNA.  Moreover, because HCMV does not infect non-human species, HCMV cannot be studied 
in vivo using laboratory animals.  Consequently, related animal cytomegaloviruses, including 
those of mouse, rat, guinea pig, and rhesus macaque have been used to investigate in vivo aspects 
of cytomegaloviral disease.  Of these, GPCMV serves an important role as the only small animal 
cytomegalovirus that is congenitally transmitted (125).  
 This simplicity of the GPCMV genome has been particularly useful for studying 
phenomena involving genomic termini, including genome circularization, concatemer cleavage, 
and the duplication of terminal repeats that occurs in conjunction with DNA cleavage (78, 80, 
95).  Previous work from the McVoy laboratory examined the effects of BDCRB on GPCMV at 
the molecular level (94).  In contrast to studies on HCMV (68, 143), BDCRB did not block the 
formation of monomeric GPCMV DNA or its insertion into capsids.  This packaged DNA, 
however, was abnormal in three ways: (i) it was exclusively type II at the right end (Figure 16-
B); (ii) it was truncated heterogeneously, missing 2.7 to 4.9-kb of left-end sequences; and (iii) it 
appeared to be packaged within capsids but these capsids were retained in the nucleus and failed 
to protect their DNA from exogenously added nuclease.  From these studies, it was concluded 
that BDCRB does not impair GPCMV DNA packaging per se, but selectively alters the 
cleavage/packaging process, possibly by inducing premature cleavage events; the resulting 
truncated genomes are packaged within capsids, but subsequent steps that normally render 
capsids impermeable to nuclease fail to occur (94).  
 The goal of this study was to isolate and characterize a BDCRB resistant mutant.   
Results 
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Generation of a BDCRB-resistant virus 
 To isolate a GPCMV having mutations conferring resistance to BDCRB, wild type 
GPCMV was serially passaged in the presence of 50 µM BDCRB until efficient replication was 
evident.  This stock was passaged several additional times in 75 µM concentrations of BDCRB.  
Several rounds of 96-well limiting-dilution cloning were used to purify a virus designated R-75 
from this stock.  Growth curves were conducted to determine if R-75 is resistant to BDCRB.  
Cells were infected with wild type GPCMV or R-75 at low MOI (0.01) in the presence or 
absence of 50 µM BDCRB and the titers of the resulting culture supernatants were determined 
on days three, five, and seven post infection.  Consistent with previous observations, wild type 
virus reached peak titers of ~107 pfu/ml by 7 days p.i.  50 µM BDCRB reduced peak titers on 
day seven by four logs (Figure 15).  R-75 exhibited no significant growth defects in the absence 
of BDCRB, reaching a peak titer on day seven slightly higher than that of wild type.  In contrast 
to wild type, the R-75 peak titer on day seven was only reduced 5-fold by 50 µM BDCRB, 
indicating resistance to BDCRB on the order of 3 logs relative to the sensitivity of wild type 
virus (Figure 15). 
R-75 contains a nucleotide change that results in a single amino acid change in GP89 
In HCMV, mutations conferring resistance to BDCRB and TCRB result in amino acid 
substitutions in either of the two terminase subunits UL56 and UL89 (68, 143).  Mutations were 
also found in the UL104 portal protein, but as these mutations were present in conjunction with 
terminase mutations and did not confer resistance on their own it was proposed that they may 
arise as compensatory mutations that confer growth advantages to viruses having resistance 
mutations in terminase (66).  To identify potential resistance mutations in R-75, 
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Figure 15:  Viral growth curves in the presence or absence of BDCRB.  Cells were infected 
with wild type GPCMV (wt), R-75, or BVD at an MOI of 0.01 in the presence or absence of 50 
µM BDCRB.  The titers of the culture supernatants (pfu/ml) were determined on days 3, 5, and 7 
post infection and plotted on a log10 scale.   
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the GPCMV terminase genes GP56 and GP89 and the portal protein gene GP104 were 
sequenced from wild type virus and R-75.  No mutations were identified in GP56 or GP104; 
however, R-75 had a single nucleotide change in GP89 that conferred a predicted L409P amino 
acid change in the terminase subunit GP89.  This residue lies near but not within the cluster of 
previously identified mutations associated with benzimidazole and BAY38-4766 resistance 
(Figure 16-A). 
The genome of R-75 has a large deletion and a small insertion 
Serial passage of herpesviruses can result in deletions, rearrangements, and formation of 
defective genomes.  To determine if R-75 has any large alterations in genome structure, virion 
DNAs were digested with restriction enzymes with HindIII, EcoRI, and XbaI, separated by 
agarose gel electrophoresis, and visualized by ethidium bromide staining.  The R-75 restriction 
patterns revealed significant alterations in the R-75 genome.  XbaI M and L were clearly absent 
from R-75 DNA (Figure 17-A), indicating a sizeable deletion within the HindIII E region of the 
genome (see restriction map, Figure 17-C).  Moreover, terminal fragments from both the left end 
(HindIII R, EcoRI Y, and XbaI N) and the right end (HindIII M) of the genome were present but 
at greatly reduced levels (Figure 17-A).  With these exceptions, the HindIII, XbaI, and EcoRI at 
restriction patterns of R-75 matched that of wild type virus (Figure 17-A), indicating no 
additional large rearrangements elsewhere in the R-75 genome. 
Southern hybridization using HindIII E sequences as the probe confirmed that XbaI L and 
M, as well as two smaller intervening fragments, XbaI j and n, were absent from R-75 DNA 
(Figure 17-B).  The 18-kb HindIII E fragment in wild type DNA was absent from R-75 DNA and 
replaced by a ~6-kb fragment (Figure 17-B), again consistent with a large deletion internal to 
HindIII E.  Similar Southern hybridization experiments using SmaI, BglII, and AclI digestions, 
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Figure 16:  Clustering of amino acid terminase mutations associated with drug resistance.  
(A) Amino acids 343-410 of HCMV UL89 are shown aligned with homologous proteins from 
MCMV (M89) and GPCMV (GP89) to illustrate the proximity of mutations associated with 
resistance: D344E, S345A and A355T in UL89 confer BDCRB/TCRB-resistance (68, 143); 
M360I in M89 confers resistance to BAY38-4766 (15), whereas D358N (UL89) and M357V 
(GP89) have been identified in BAY 38-4766-resistant viruses (15, 127) but have not been 
genetically confirmed to confer resistance.  The L409P mutation in R-75 identified in this study 
is also shown.  Note that residue numbers are specific to each virus.  Amino acids in the wild 
type sequences that are altered by mutations are shown in bold.  (B) Genomic terminal ends of 
GPCMV denoting the difference in type I and type II, type I has an a sequence on the left 
terminal end while type II has a sequences on both terminal ends. 
UL89
M89
GP89
OR
type I
MR
type II
L N V V S Y V C E E H
L N V V S Y V C E E H
L N V I S Y V C E E H
S D S T C F L T R L N N A P F D M
S D S T C F L T K L T S A P F D M
T S A T C F L T R L S N S P F D M
D!
3!
4!
4!
E
A
3!
5!
5
T
S!
3!
4!
5!
A
M
3!
6!
0!
I
D
3!
5!
8
N
M
3!
5!
7
V
L H S F T E
I Q A F S E
M R A F S E
UL89
M89
GP89
K G D A T A C P C Y R L H
K G D A T A C P C Y R L H
K G D A T A C P C Y R L H
K P T F I S L N S Q V R K T A N M F M P G
K P T F I T L N S D V R K T A N M F M P G
K P T F I T I S S E V R K T A N M F L A G
L
4!
0!
9!
P
A.
B.
3!
4!
3
3!
7!
6
3!
7
7
4
1
0
 
 
61 
which cleave frequently within HindIII E, again identified fragments that were missing from or 
unique to R-75 (not shown).  These results served to narrow the region of the deletion to within a 
few kilobases.  PCR reactions were conducted on each side and progressively closer to the region 
of the deletion until reactions were observed that failed to amplify R-75 DNA, yet generated the 
expected PCR products from wild type DNA (not shown).  Failed reactions were presumed to at 
least partially overlap the deleted region.  Appropriately oriented primers from the two closest 
flanking reactions that successfully amplified R-75 DNA were combined in a reaction expected 
to span the breakpoint of the deletion.  The primer pair 13F and 9R was found to amplify a 2.0-
kb PCR product from R-75 DNA but did not amplify wild type DNA (not shown).  Cloning and 
sequencing of this PCR product revealed the breakpoints of the deletion, which spans 12,433-bp 
of viral sequence.  In addition, 743-bp of non-viral (presumably host-derived) sequence was 
inserted between the deletion breakpoints.  These results were confirmed using R-75 virion DNA 
directly as the template for sequencing reactions.  Open reading frame analysis of the HindIII E 
sequence indicates that several potential viral genes are deleted or disrupted in R-75 (Figure 17-
C).  BLASTP performed on 05/05/2011 failed to identify sequence homologs for four of these 
ORFs, but the remaining four are homologs of the HCMV US22 family of proteins, exhibiting 
homology to HCMV US22, US23, and US24.   
The genome of R-75 has extensive reiterations of the terminal repeat 
 As illustrated in Figure 16-B, GPCMV virions contain a roughly equal mixture of two 
genome types.  Type II genomes have a single copy of the 1-kb terminal repeat at each end, 
whereas type I genomes lack this repeat at the right end.  The restriction pattern analyses 
described in the previous section indicated that restriction fragments from both ends of the R-75 
genome were under-represented.  To investigate this further, Southern hybridization was used to  
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Figure 17:  R-75 has a large deletion.  (A) Virion DNAs from wild type GPCMV (wt) and R-
75 (75) were digested with restriction enzymes with HindIII, EcoRI, or XbaI, separated by 
agarose electrophoresis, stained with ethidium bromide, and visualized with UV light.  The 
positions of molecular weight markers are shown on the left.  Arrows indicate the locations of 
left-end terminal fragments HindIII R, EcoRI Y, and XbaI N, right-end terminal fragment 
HindIII M, and internal fragments XbaI L and M.  (B) The gel shown in panel A was transferred 
to a nylon membrane and hybridized with a probe consisting of GPCMV HindIII E sequences.  
Arrows indicate the locations of HindIII E, EcoRI A, and XbaI L, M, j, and n fragments in wild 
type DNA.  (C) Schematic illustrating the HindIII map of the GPCMV genome as derived by 
Gao and Isom (44).  An XbaI map of the HindIII E region is expanded below.  Assignments of 
XbaI fragments predicted by the sequence as XbaI M, L, j, and n are based on their observed 
molecular weights and correspondence to physical mapping data (44).  The locations of PCR 
primers 13F and 9R, used to determine the sequence of the break point region, are indicated 
below the XbaI map.  The light gray box indicates sequences that are deleted from the R-75 
genome; the 743-bp insertion is not shown.  The light gray striped box indicates sequences that 
are deleted from the BVD genome.  Black arrows at the bottom indicate open reading frames that 
are removed or disrupted by the deletions in R-75 and BVD; homologies with known HCMV 
genes are indicated.  
 
 
 
64 
detect terminal restriction fragments.  HindIII, ClaI, and KpnI digests were hybridized with 
probes to detect terminal fragments from either the right (Figure 18-A) or left (Figure 18-B) ends 
of the genome.  Restriction maps, probe locations, and predicted fragment sizes are indicated in 
Figure 18-C.  At the right end, wild type virion DNA contained predominantly O and M 
fragments (Figure 18-A), reflecting the expected preponderance of type I and II genomes having 
zero or one repeat, respectively; however, trace amounts of fragments larger by 1 or 2-kb 
(designated M+1, M+2) were also detected.  As the terminal repeat is 1-kb in length, M+1 and M+2 
fragments were interpreted as reflecting low levels of termini having one or two additional 
repeats, as illustrated in Figure 18-C.  R-75 virion DNA contained reduced levels of O and M 
fragments.  Regardless of the restriction enzyme used, a ladder of larger fragments was detected 
having a size periodicity of approximately 1-kb (Figure 18-A).   
Very similar results were obtained when probing the left end of the genome.  Wild type 
virion DNA exhibited the expected preponderance of R fragments containing one repeat but 
small amounts of fragments larger by 1 or 2-kb (R+1, R+2) were also present (Figure 18-B).  R-75 
DNA contained trace amounts of R and a ladder of fragments increasing in size with a 
periodicity of approximately 1-kb (Figure 18-B). 
Based on the restriction maps for these enzymes there is no obvious way that partial 
digestion could result in ladders with 1-kb periodicity; moreover, it is a virtual impossibility that 
partial digestions could yield the same periodicity at both ends of the genome with three different 
enzymes.  The conclusion from digestion with three different enzymes is that the ladders are not 
the result of incomplete digestion by the restriction enzymes, but rather, reflect the presence of 
termini with additional copies of the 1-kb terminal repeat.  Thus, although some R-75 genomes 
retain normal R, M, and O termini, the majority of R-75 genomes have additional terminal  
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Figure 18:  Genomic termini and concatemer junctions of R-75 have extensive reiterations 
of the terminal repeat.  (A) Virion DNAs from wild type (wt) or R-75 (75) were digested with 
restriction enzymes with HindIII, ClaI, or KpnI and separated by agarose electrophoresis, 
transferred to a nylon membrane, and hybridized with the right end-specific O probe.  (B) Virion 
or concatemeric DNAs were digested with HindIII or ClaI and hybridized with left end-specific 
R probe.  The positions of molecular weight markers are indicated to the left of each Figure; 
arrows indicate the locations of right-end terminal fragments (O and M), left end terminal 
fragments (R), and junction fragments (OR and MR).  Fragments postulated to have additional 
terminal repeats are designated as illustrated in panel C.  (C) Schematics illustrating the right and 
left ends of the R-75 genome as well as concatemeric junctions.  Repeats are represented by gray 
boxes and the predicted sizes of selected restriction fragments are indicated in parentheses.  
Fragments are designated with a superscript +n, where n = the number of additional repeats that 
they contain (for simplicity, fragments with more than three repeats are not shown).  Black bars 
indicate the sequences contained in the hybridization probes used.   
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repeats present in variable numbers.  Upon overexposure, fragments with up to eight additional 
repeats could be detected (not shown).   
Concatemer junctions in R-75 also contain extensive reiterations of the terminal repeat 
In a previous study, Nixon et al. (95) derived a GPCMV mutant that forms only type II 
genomes and hence has one copy of the repeat at each end.  Nixon hypothesized that if cleavage 
is a simple cut of the DNA, the concatemeric junctions from which the mutant genomes are 
cleaved must contain two adjacent copies of the repeat such that cleavage between them leaves 
one copy on each newly formed end.  However, the concatemeric junctions that were observed 
for this mutant contained predominantly one copy of the repeat, and this led us to conclude that 
GPCMV has the capacity to duplicate terminal repeats during the cleavage process (95).  It was 
postulated whether the extensive repeat reiterations on the ends of R-75 genomes arise by a 
simple mechanism of cleavage within already extensive arrays of reiterated repeats, or 
alternatively, by a more complex process in which concatemer junctions contain a relatively 
small number of repeats but these undergo extensive duplication during cleavage.    
Concatemeric DNA was isolated from cells infected with wild type or R-75, digested 
with restriction enzymes with ClaI, separated by electrophoresis, and hybridized with the R 
probe.  As R terminal fragments are not present on concatemer ends (80), this probe should 
detect only junction fragments in concatemeric DNA.  Consistent with previous observations 
(95), wild type concatemer junctions consisted predominantly of single repeat-containing OR and 
double repeat-containing MR fragments, although small amounts of MR+1 and MR+2 were 
present (Figure 18-B).  In contrast, R-75 concatemer junctions contained reduced levels of OR 
and MR and a ladder of larger fragments having a periodicity of approximately 1-kb (Figure 18-
B).  The absence of R, R+1, and R+2 clearly demonstrates that concatemer DNA was not 
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contaminated with genomic DNA; hence, the larger fragments that were detected must represent 
junctions rather than terminal fragments derived from contaminating genomes.  These results 
confirmed the hypothesis that the repeat reiterations on the termini of R-75 genomes are derived 
from cleavage of arrays of reiterated repeats at concatemer junctions.  Therefore, although repeat 
duplication must play a role in the initial accumulation of the repeat arrays, once these arrays 
have been generated, extensive duplications are not required during each cleavage event.   
Additional terminal repeats may have accumulated prior to the HindIII E deletion. 
Given that herpesviruses have an optimal size range for efficient genome packaging (10), 
the above results suggested two likely scenarios: (i) the terminal repeats accumulated first and 
the deletion occurred to compensate for an over-length genome; or (ii) the deletion occurred first 
and additional terminal repeats arose to compensate for an under-length genome.  Cui et al. 
recently used viruses derived from BAC clones of the GPCMV genome to investigate the impact 
of under or over-length genomes (27).  Using a full length BAC clone, Cui et al. (27) transfected 
cells under conditions that would not allow cre-mediated excision of the 8.8-kb BAC origin.  
Thus, the resulting viruses were predicted to have genomes that were 8.8-kb over-length.  Virion 
DNAs prepared following two independent transfections were deficient in XbaI L and M 
fragments, indicating that in both cases spontaneous deletions had occurred. 
Cui et al. (27) further used BVD and another spontaneous deletion mutant, N2, to 
evaluate the impact of under-length genomes.  By removing or retaining the 8.8-kb BAC origin, 
Cui was able to evaluate two versions of each virus.  Virus N2cre has a genome that is 17.9-kb 
under-length due to a single large deletion near the left end of the genome, whereas retention of 
the 8.8-kb BAC origin in virus N2 resulted in a virus with a 9.1-kb under-length genome.  
Similarly, virus BVDcre has a 15.1-kb under-length genome, while virus BVD retains the BAC 
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origin and has a 6.3-kb under-length genome.  BVD and BVDcre grew with wild type growth 
kinetics, whereas N2 and N2cre had a one log reduction in peak titer.  Modulation of genome 
length by removal or retention of the BAC origin had no apparent impact on replication kinetics 
or efficiency (27).  These findings revealed that replication efficiency is not impacted by 
reductions in genome length of up to 15.1-kb.  While N2cre had a growth defect, that was not 
ameliorated by the less under-length N2 genome suggested that the defect is more likely related 
to loss of augmenting genes in the deleted region than genome length (27).   
These studies, however, did not address the possibility that genomes predicted to be 
under-length may have grown in length by increasing the number of terminal repeats either 
rapidly or gradually upon passage after reconstitution from BAC DNAs.  I therefore sought to 
evaluate the termini of BVD, BVDcre, N2, and N2cre shortly after reconstitution or after a 
subsequent 35 passages in cell culture.  Prior to serial passage, N2 and N2cre virion DNA was 
prepared from non-passaged stocks, digested with HindIII, and fragments separated on an 0.8% 
agarose gel and transferred to a nylon membrane.  The membrane was probed with pGP21 to 
detect M, O, and R fragments.  The results, shown in Figure 19 –A confirmed the virion DNA 
and the BAC DNA did not have reiterations.  The MR fragment was detected confirming the 
right and left ends are joined in BAC DNA.  In Figure 19-B, after 35 passages these viruses did 
not acquire additional repeats at their R termini.  While faint M+1,+2,+3 fragments were observed 
in all four viruses and were lacking in the wild type parental virus, their significance is unclear as 
similar faint fragments are sometimes seen in wild type stocks (Figure 18-B) and these fragments 
were present in the early passage BVD and N2 stocks (Figure 19-A).  Nevertheless, the data 
clearly demonstrate that these viruses did not acquire the extensive number of terminal repeats 
and corresponding diminution in M and R fragments observed for R-75.  I therefore concluded 
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Figure 19: Under-length genomes do not accumulate reiterated terminal repeats.  (A.) The 
N(2) and N(2)cre viruses prior to serial passage.  Virion DNA was prepared from non-passaged 
stocks, digested with HindIII, and fragments separated on a 0.8% agarose gel and transferred to a 
nylon membrane.  The membrane was probed with pGP21 to detect M, O, and R fragments.  (B.) 
The indicated viruses were passaged 35 times after reconstitution from BACs.  Virion DNAs 
prepared from the resulting stocks were digested with HindIII.  Fragments were separated on an 
0.8% agarose gel and transferred to a nylon membrane.  The membrane was probed with pGP48 
to detect M and R fragments.  The locations of DNA size markers (kb) are shown on the left. 
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 that after 35 passages in cell culture the genomes comprising these viral stocks did not exhibit 
significant changes in the number of terminal repeats, and therefore, the extensive terminal 
repeats observed on R-75 genomes are unlikely to have resulted from serial passage of a genome 
rendered under-length by the deletion in HindIII E.  Taken together, the results presented above 
support the first scenario that the deletion in R-75 occurred in response to the genome becoming 
over-length due to accumulation of terminal repeats.   
The deletion in HindIII E is not responsible for BDCRB resistance 
To address the possibility that the BDCRB resistance of R-75 may be related to loss of 
one or more genes in the deleted region, BVD was evaluated for sensitivity to BDCRB.  As the 
BVD deletion is slightly larger (15.1-kb) and removed more sequences on both ends than that of 
R-75 (Figure 17-C), I reasoned that all of the genes that are inactivated by the deletion in R-75 
are also inactivated in BVD.  Growth curves of BVD in the presence and absence of BDCRB 
clearly demonstrated that BVD is not resistant to BDCRB (Figure 15).  Resulting in the 
conclusion that the resistance of R-75 to BDCRB does not arise from the lack of one or more 
genes in the HindIII E region. 
Discussion 
In order to better understand how BDCRB mediates these effects on GPCMV, wild type 
GPCMV was serially passaged in the presence of BDCRB to derive a BDCRB-resistant mutant.  
This virus exhibited dramatic genetic and genomic structural alterations that are, to our 
knowledge, unprecedented in the herpesvirus literature.  Understanding the mechanisms by 
which these alterations arise and determining which alterations confer resistance to BDCRB 
should serve to advance our understanding of the mechanisms of action of this class of drugs and 
to elucidate further the molecular mechanisms that underlie herpesvirus genome maturation. 
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The halogenated benzimidazoles, including BDCRB, were the first compounds 
discovered that inhibit herpesvirus maturation (143).  Despite their nucleosidic structure they do 
not inhibit DNA synthesis, but rather affect the formation of monomeric genomes from 
concatemeric replicative intermediate DNA (68, 143).  In the case of HCMV, the amount of 
monomeric DNA formed is drastically reduced and a supergenomic HCMV DNA species named 
“monomer-plus” is formed at low levels (143) (see Chapter 5).  McVoy et al. and I ((77) and 
Chapter 5) have hypothesized that monomer-plus is formed because BDCRB causes the HCMV 
terminase to skip the normal cleavage site and to continue to package DNA until a second 
cleavage site is encountered 30-kb further along the concatemer.  In GPCMV, the response to 
BDCRB is somewhat different.  Monomer length genomes are abundantly produced but they are 
truncated slightly at the left end (94).  Thus, in both viruses, BDCRB modifies the way in which 
terminase recognizes and cleaves DNA, but in slightly different ways: the GPCMV terminase is 
made less selective and prone to cleave prematurely, whereas the HCMV terminase is less 
efficient at recognizing its proper cleavage site and prone to cleavage site skipping.   
These markedly different effects suggest that HCMV and GPCMV terminases may differ 
somewhat in their interactions with BDCRB.  To gain additional insights into these interactions a 
GPCMV was derived that has acquired the ability to replicate efficiently in the presence of 
BDCRB.  The resistant virus has three notable genetic changes:  a mutation resulting in a single 
amino acid change (L409P) in the GP89 terminase subunit, a large deletion in the HindIII E 
region, and a substantial increase in the number of terminal repeats present at both ends of the 
genome and at concatemer junctions.   
The L409P mutation in GP89 lies near but not directly within the amino acid 344-355 
region that in HCMV UL89 has been implicated, by clustering of resistance mutations (Figure 
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16-A), as a potential BDCRB-interaction site (68, 143).  This may suggest that GP89 and UL89 
differ with respect to the regions that interact with BDCRB.  Such differences in interactions 
could underlie the disparities between BDCRB’s affects on GPCMV and HCMV.  However, this 
conclusion should be considered tentative, as the L409P mutation is at present only associated 
with resistance and has not been rigorously demonstrated to confer resistance when introduced 
into an otherwise wild type background.   
How R-75 acquired additional terminal repeats and what role they may play in BDCRB 
resistance are not known.  The terminal repeats of wild type GPCMV appear to be duplicated 
during DNA cleavage but are again lost, perhaps by homologous recombination, during the early 
stages of concatemer synthesis (95).  Although the vast majority of genomic termini of wild type 
GPCMV have one or zero repeat copies, low levels of termini with one or two additional repeats 
can be detected (Figure 18) (78).  This suggests that additional repeats can accumulate but that 
extensive reiterations are not favored, perhaps due to a restriction imposed by the packaging 
capacity of the capsid.  Thus, the deletion of HindIII E sequences in R-75 may have shortened 
the genome and permitted the spontaneous accumulation of additional repeats.  Although the 
simplicity of this hypothesis is attractive, it appears to be incorrect.  It predicts that any internal 
deletion should gradually give rise to accumulation of additional terminal repeats, yet serial 
passage of GPCMVs with genomes up to 17.9-kb under-length showed no evidence of acquiring 
such additional repeats (Figure 19). 
Conversely, accumulation of additional repeats may have occurred in response to 
BDCRB selection.  The additional repeats rendered the genome over-length, which forced a 
compensatory deletion in HindIII E.  Consistent with this hypothesis, Cui et al. (28) found that 
over-length GPCMV genomes rapidly undergo compensatory deletions that frequently lie within 
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the HindIII E region.  Moreover, a fact that the HindIII E deletion in the BVD mutant appears to 
provide no growth advantage in the presence of BDCRB suggests that the deletion in R-75 is 
unlikely to have arisen directly in response to BDCRB selection.   
How might have BDCRB driven the accumulation of additional repeats?  One possibility 
is that the L409P mutation in GP89 may alter terminase function in such a way that favors the 
accumulation of repeats.  This is reasonable given that repeat duplication is postulated to occur in 
conjunction with DNA cleavage (12).  However, another intriguing possibility is that multiple 
repeats at concatemer junctions could provide resistance to BDCRB.  Previous studies (94) 
showed that BDCRB promotes abnormal cleavages just prior to entry of the repeat (Figure 20-A).  
Shortening of the unique region of the genome (due to the deletion) might shift the point at 
which such aberrant cleavages occur to allow terminase to reach the repeat arrays.  Multiple 
cleavage sites within the arrays could give terminase additional opportunities to engage the cis 
elements that direct it where to cleave, hence overcoming the impairment to cleavage site 
recognition induced by BDCRB (Figure 20-B).  
Additional studies are clearly needed to determine which genetic alterations are 
responsible for resistance and what is the driving force in accumulation of terminal repeats.  The 
results of such studies should provide valuable insights into the processes of herpesvirus DNA 
cleavage, packaging, and terminal repeat formation, and the mechanisms by which they are 
altered or impaired by maturational inhibitors.  
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Figure 20:  Model of how terminal reiterations might confer resistance to BDCRB.  Gray 
boxes indicate terminal repeats.  (A) BDCRB treatment of wild type virus promotes premature 
cleavage, resulting in left-end-truncated genomes; terminase never encounters the cis cleavage 
sequences located in the repeats (94).  (B) The shorter unique sequence of R-75 allows terminase 
to reach the junctional repeat arrays; the repeat arrays provide terminase with multiple 
opportunities to engage cis cleavage sequences, overcoming the drug-induced propensity for 
terminase to cleave inappropriately.   
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CHAPTER 4:  A Human Cytomegalovirus Deleted of Internal 
Repeats Replicates with Near Wild Type Efficiency but Fails to 
Undergo Genome Isomerization 
Background 
In the previous chapter, I examined the effects of BDCRB on GPCMV.  To determine if 
HCMV behaves in a similar, way I needed to observe HCMV in the presence of BDCRB.  A 
property of HCMV is the ability to form four isomers of the viral genome.  GPCMV does not 
form genomic isomers.  To test our hypothesis on the formation of monomer plus in the presence 
of BDCRB, the internal junction had to be deleted.  The deletion will prevent the formation of 
genomic isomers in HCMV and may delete the formation of monomer plus.  This chapter 
describes the construction and characterization of an HCMV lacking an internal junction. 
The significance of herpesvirus genome isomerization is not known.  It is not required for 
replication as many herpesviruses do not contain inverted repeats or invertible elements (116), 
and deletion of the majority of the b'a'c' region from the HSV-1 genome gives rise to replication-
competent mutants that do not undergo genome isomerization (61, 103, 104).  While such 
isomerically “frozen” HSV-1 mutants exhibit very modest growth impairments in vitro, they are 
profoundly attenuated in vivo, suggesting that either isomerization or diploidy of genes encoded 
by bac/b'a'c' sequences are important in vivo (59, 60).  To date, HSV-1 remains the only class E 
genome virus in which isomerically frozen b'a'c' deletion mutants have been characterized.  
Moreover, no mutants have yet been constructed in which the entire b'a'c' region is deleted
 
 
77 
(HSV-1 mutants retain partial b' and c' sequences at the UL/b' and c'/US boundaries) (59).  In this 
study I sought to determine if deletion of the entire b'a'c' region from the class E genome of 
HCMV eliminates genome isomerization and how this impacts viral replication in vitro.  
Results	  
Construction of HB15∆L/S 
The HB15Tn7∆k bacterial artificial chromosome (BAC) was derived from BAC HB15 
(55).  It contains the HCMV genome (strain AD169) modified with a mini-attTn7 site in UL18 
(49), a LoxP-flanked BAC origin cassette between US1 and US2, and a short duplication of US2 
sequences that facilitates excision of the BAC cassette by homologous recombination (Figure 21-
A) (55).  To construct an HCMV genome lacking the internal b'a'c' sequences, linear 
recombination in E. coli was used to replace the b'a'c' sequences in HB15Tn7∆k with a 
kanamycin-resistance (Kn) marker.  Candidate clones were selected with kanamycin and 
screened using PCR assays spanning the predicted UL-Kn and Kn-US junctions (not shown).  
Two clones were further analyzed by XbaI restriction (not shown).  As predicted, both clones 
contained novel 1.6- and 2.3-kb XbaI fragments indicative of correct insertion of the Kn marker 
(Figure 21-A).  Clone 2 was designated HB15∆L/S. 
HB15∆L/S BAC DNA was transfected into human MRC-5 fibroblasts to determine if it 
can reconstitute a replication competent virus.  Viral cytopathic effect was detected 15 days post 
transfection and subsequent serial passage did not suggest an obvious growth defect (not shown).  
Restriction analysis of HB15∆L/S virion DNA 
To further confirm the genomic structure of HB15∆L/S and rule out possible unforeseen 
rearrangements or deletions, restriction fragment patterns for HB15∆L/S and HB15Tn7∆k virion 
DNAs were compared using a panel of restriction enzymes (Figure 21-B).  Most of the observed 
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Figure 21:  Deletion of the L/S junction from the HCMV genome.  (A) The P genome isomer 
of virus HB15Tn7Δk is shown with ab and bʹ′aʹ′ repeats flanking UL and aʹ′cʹ′ and ca repeats 
flanking US, the attTn7 site (Tn7) inserted in UL, and the BAC origin cassette (BAC) inserted in 
US.  Below is shown the HB15ΔL/S genome in which Kn replaces b'a'c'.  Sequences deleted 
from HB15Tn7Δk are indicated using nucleotide numbers that correspond to the AD169 genome 
sequence (18).  The Kn – BAC origin region is expanded below to show the predicted sizes (bp) 
of diagnostic XbaI fragments, direct duplications of US2 sequences that allow excision of the 
BAC origin by homologous recombination, and LoxP sites (P) flanking the BAC origin.  (B) 
Restriction analyses of HB15ΔL/S and HB15Tn7Δk.  Virion DNAs from HB15ΔL/S (M) and 
HB15Tn7Δk (WT) were digested with the indicated restriction enzymes.  The resulting DNA 
fragments were separated on 0.7% agarose and visualized with ethidium bromide and UV light.  
Colored boxes indicate fragments that are lost or created in HB15ΔL/S by deletion of b'a'c' 
(green), fragments that are unique to HB15ΔL/S by virtue of the Kn insertion (red), fragments 
that indicate retention of the BAC cassette in HB15ΔL/S (yellow), IS isomer S-terminal 
fragments missing from HB15ΔL/S (white), and a P isomer S-terminal fragment that is half-
molar in HB15Tn7Δk and equi-molar in HB15ΔL/S (blue).   
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restriction pattern differences were predicted by deletion of b'a'c' sequences (Figure 21-B, green 
boxes) or insertion of Kn (Figure 21-B, red boxes), or were consistent with retention of the BAC 
origin cassette in HB15ΔL/S and its excision from HB15Tn7∆k (Figure 21-B, yellow boxes).  
The latter results were not surprising given that excision is largely driven by selection against the 
packaging of over-length genomes and even with the BAC cassette retained the HB15ΔL/S 
genome is under-length, while that of HB15Tn7∆k would be significantly over-length were the 
BAC cassette not excised.  The remaining differences could be attributed to a failure of the S 
segment of HB15ΔL/S to invert.  In HB15Tn7∆k, terminal restriction fragments can differ in size 
according to the orientations of the L or S segments if the restriction site nearest the genome end 
falls within UL or US.  Thus, L or S segment inversion can be detected by the presence of 
terminal fragments unique to IL or IS genomes.  Table 4 shows predicted terminal fragment sizes 
for the enzymes used here.  MfeI and XbaI cut within the b repeat and therefore L terminal 
fragments from P and IL genomes are identical, while for the remaining enzymes the L terminal 
fragments were too large to resolve.  Hence, this analysis was unable to evaluate L segment 
inversion.  However, several S-terminal fragments unique to IS genomes were easily resolved 
and in each case were present in HB15Tn7∆k DNA but absent from HB15ΔL/S DNA (Figure 
21-B, white boxes), indicating that the S segment of HB15ΔL/S does not invert.  Failure of the S 
segment to invert further predicts that S terminal fragments from the P orientation should be 
equi-molar in HB15ΔL/S since all genomes should have this S end, while in HB15Tn7∆k the 
same fragments should be half-molar since half the genomes have a different S end.  This was 
clearly the case for the 3.5-kb S-terminal MfeI fragment (Figure 21-B, blue box). 
Southern analysis of HB15∆L/S virion DNA 
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The agarose-separated fragments shown in Figure 21-B were transferred to a nylon 
membrane and hybridized with probes pON1101 to detect fragments internal to the BAC origin, 
pON227 to detect restriction fragments from the L end of the genome, and pON2333 to detect 
fragments from the S end of the genome.  The latter two probes are predicted to hybridize to 
junction fragments in addition to terminal fragments.  The predicted fragment sizes for each 
enzyme are given in Table 4.   
The pON1101 probe failed to hybridize to HB15Tn7∆k DNA, confirming that the BAC 
origin had efficiently self-excised from the HB15Tn7∆k genome (Figure 22).  For HB15ΔL/S 
DNA each restriction digest contained a fragment that hybridized to pON1101 and had a size 
consistent with retention of the BAC origin in HB15ΔL/S (Figure 22).  The sequence-based size 
predictions for these fragments are: BglII, 3.65-kb; HindIII, 3.9-kb; SnaBI, 3.3-kb; MfeI, 5.8-kb; 
NheI, 8.5-kb; and XbaI, 5.6-kb.  
In HB15Tn7∆k DNA, the pON227 probe detected the 12-kb NheI L-terminal fragment 
from P genomes as well as several larger hard to resolve fragments including the 21-kb L-
terminal fragment from IL genomes and junction fragments from P, IL, IS, and ILS genomes 
(Figure 23).  Similar results were obtained for SnaBI fragments probed with pON227 and for 
MfeI and XbaI fragments probed with pON2333.  In each case, all of the larger junction 
fragments were missing from HB15ΔL/S DNA (Figure 23).  The lack of P junctions were 
predicted due to the deletion, however, the lack of IL, IS, and ILS junctions clearly demonstrates 
that HB15ΔL/S fails to undergo both S and L segment inversion.  
In some digests, terminal fragment size differences were sufficient to differentiate IL or IS 
genome ends from P genome ends.  HindIII analysis provided clear evidence that the L segment 
of HB15ΔL/S does not invert as the 12.6-kb HindIII IL L-terminal fragment was clearly resolved  
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Table 4:  Sizes* (kb) of Terminal and Junction restriction fragments for the four genomic 
isomers 
 
L-terminal  S-terminal  Junction 
P IL  P IS  P IL IS ILS 
BglII 31.1 18.0  12.7 17.7  35.2 48.3 30.2 43.3 
HindIII 17.2 12.6  17.7 7.0  19.0 23.6 29.7 34.4 
SnaBI 11.4 11.5  14.5 3.6  14.5 14.5 25.4 25.3 
MfeI 6.5 6.5  3.5 2.6  8.6 8.6 9.4 9.4 
NheI 12.0 21.1  21.6 4.5  25.0 15.9 42.2 33.0 
XbaI 8.0 8.0  11.2 11.5  18.9 18.9 18.6 18.6 
*Junctions and L-termini can contain one to several a sequences, whereas S-termini 
contain predominantly zero or one a sequence (135, 136).  Sizes given are for fragments 
that contain one a sequence.   
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in HB15Tn7∆k DNA but absent from HB15ΔL/S DNA (Figure 23).  Similarly, as noted above, 
HB15ΔL/S DNA lacked hybridizing fragments migrating in the region where the 21-kb NheI IL  
L-terminal fragment should migrate (Figure 23).  Due to the large sizes of these fragments, the 
heterogeneity that occurs at both junctions and termini as a result of variable reiterations of the 
0.5-kb a sequence (135, 136) were not apparent.  However, the MfeI S-terminal fragments were 
small enough to reveal variations in the number of terminal a sequences and hence these patterns 
contained additional fragments that formed ladders with ~0.5-kb increments.  S-terminal MfeI 
fragments from P genomes (3.0-, 3.5-, and 4.0-kb fragments representing S-termini with zero, 
one, and two a sequences, respectively) were present on both genomes.  However, the 2.1- (no a 
sequence) and 2.6-kb (one a sequence) fragments indicative of IS genomes were present in 
HB15Tn7∆k but absent from HB15ΔL/S DNA (Figure 23), again confirming that HB15ΔL/S 
fails to undergo S segment inversion.  
HB15ΔL/S replicates with a slight growth impairment relative to HB15Tn7∆k 
To determine if failure to isomerize or deletion of the internal L/S junction has an impact 
on viral replication, single step (MOI=4) and multistep (MOI=0.01) growth curves were 
performed with HB15ΔL/S, its parental virus HB15Tn7∆k, and AD169 (the strain from which 
HB15Tn7∆k was derived).  Interestingly, HB15Tn7∆k replicated to slightly higher titers than 
AD169, suggesting that our AD169 stock, which was obtained from ATCC in 1980, may have 
diverged from the stock that was used to construct HB15Tn7∆k (55).  While this comparison 
serves as a measure of intrastrain variation, the valid comparison is between HB15ΔL/S and its 
parental, HB15Tn7∆k.  Under both MOI conditions, HB15ΔL/S achieved titers approximately 1-
1.5 logs lower than those of HB15Tn7∆k and at low MOI exhibited somewhat delayed kinetics 
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Figure 22:  The BAC origin is lost in HB15Tn7Δk.  DNA fragments from the gel in Figure 14-
B were transferred to a nylon membrane and hybrized with pON1101 to detect sequences 
specific for the BAC origin.  WT denotes HB15Tn7Δk and M denotes HB15ΔL/S.  Positions of 
DNA size standards (kb) are indicated on the left. 
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Figure 23:  Southern analyses of HB15ΔL/S and HB15Tn7Δk.  DNA fragments from the gel 
shown in Figure 21-B were transferred to a nylon membrane and sequentially hybridized with 
probe pON227 to detect L-terminal fragments and junctions or with pON2333 to detect S-
terminal fragments and junctions.  The sizes (kb) of relevant restriction fragments are indicated. 
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 (Figure 24).  While these differences could be attributable to intrastrain variation (as suggested 
by the range between HB15Tn7∆k and AD169), it should be noted that while the AD169 and 
HB15Tn7∆k stocks are distantly related, the HB15ΔL/S and HB15Tn7∆k are not; both were 
amplified through limited passage after reconstitution from their respective BAC DNAs.  Thus, it 
is likely that, similar to HSV-1 isomerically frozen mutants, deletion of HCMV b'a'c' sequences 
results in modest decreases in viral replicative fitness.   
Discussion 
Structurally complex genomes able to form multiple genome variants are a hallmark of 
the Herpesviridae.  Isomerization, the process of segment flipping due to recombination between 
inverted repeats, is common in viruses of the alpha subfamily; arrays of reiterated direct repeats 
that vary in length depending on the number of repeat copies are a common feature of genomes 
from the gamma subfamily; whereas in the beta subfamily direct terminal repeats that are 
sometimes reiterated but often single copy are common.  Unique among betaherpesviruses is the 
highly complex class E genome of HCMV.   
Early on, the class E genome structure of HSV-1 and the phenomenon of isomerization 
was believed to be integral to and perhaps demonstrative of a unique mechanism of DNA 
replication.  This idea was disproved when it was found that HSV-1 mutants deleted of their 
internal repeats do not isomerize yet are replication competent in vitro (61, 103, 104).  Moreover, 
the fact that a virus that normally does not isomerize (murine CMV) can gain the ability to 
isomerize simply by artificial creation of inverted repeats (81) further suggested that there is 
nothing unique about the replication mechanisms or enzymatic machinery of viruses that 
isomerize versus those that do not – probably any herpesvirus genome will isomerize during 
replication if it contains inverted repeats.  Thus, isomerization appears to have arisen by 
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Figure 24:  Growth curves of virus strain AD169 and BAC-derived viruses HB15ΔL/S and 
HB15Tn7Δk.  Carefully matched inocula of each virus were used to infect MRC-5 cells at MOIs 
of 0.01 (A) or 4 (B) and titers of infectious virus in the culture supernatants were determined on 
the days indicated. 
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 serendipity, a consequence of accidental acquisition of inverted repeats and a replication 
mechanism that is highly recombinagenic by nature.   
Even so, inverted repeats have been retained in the genomes of many herpesviruses and 
this suggests a replicative advantage in vivo, if not in vitro.  Indeed, isomerization-defective 
HSV-1 mutants have been shown to be attenuated in vivo (59, 60), but this could be an effect of 
gene dosage rather than an advantage conferred by isomerization, since by necessity these 
studies compared wild type HSV-1, in which genes within the repeats are diploid, to 
isomerization-defective mutants in which these genes are haploid.  Thus, inverted repeats may 
serve as a stable way to double the dosage of certain genes.  Alternatively, isomerization and/or 
the presence of an internal cleavage site may be important in certain species, tissues, or cell types.  
Although noninverting mutants of HSV-1 replicate well in cell culture, they failed to replicate 
locally in corneal or brain tissues of mice following direct inoculation (59).  Similarly, 
acquisition of a class E genome by pseudorabies virus provides a growth advantage in chicken 
cells and in chickens and a disadvantage in rabbit cells and in mice (113).  The growth defect in 
rabbit cells was linked to inefficient genome packaging associated with pronounced alterations in 
the structure of concatemeric DNA (110).   
Here, I sought to ascertain whether HCMV would tolerate deletion of its b'a'c' sequences, 
whether this would result in an isomerization-defective genome, and whether this would impact 
the efficiency of viral replication in vitro.  The results clearly demonstrate that like in HSV-1, 
deletion of the b'a'c' sequences results in an isomerization-defective HCMV that replicates with 
nearly wild type efficiency, at least in fibroblast cells.  This is the first class E genome in which 
the b'a'c' region has been fully deleted and the first characterization of an isomerically frozen 
class E mutant other than HSV-1.  These results are similar to those obtained with HSV-1 
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mutants, in that HB15ΔL/S is replication competent but exhibits a modest growth impairment 
relative to its parental virus (104).  As for the HSV-1 frozen mutants, the growth defect could 
either derive from changes in gene expression or the inability to isomerize.   
That the HCMV genes encoded within the deleted b'a'c' sequences are dispensable was 
largely predictable from prior studies.  The two haploid genes that are disrupted in HB15ΔL/S, 
IRL13 and IRS1, have been individually deleted without impact on replication in fibroblasts (9, 
37, 64, 159).  The remaining genes, all within b', are diploid in HB15Tn7∆k but haploid in 
HB15ΔL/S.  However, it is important to note that these genes are not normally diploid.  The 
strain AD169 genome has large 11-kb b repeats, whereas the b repeats of HCMV clinical strains 
are typically smaller than 1-kb.  Current evidence suggests that during in vitro propagation of 
strain AD169 a ~10-kb region of UL encoding RL1-RL12 was duplicated, inverted, and inserted 
adjacent to b', greatly expanding the b repeats and rendering RL1-RL12 diploid (109).  However, 
haploidy of these genes does not necessarily result in impaired growth.  The varL variant of 
strain Towne has 60-bp b repeats, is haploid for all of the diploid b sequence genes of AD169 
(13), yet replicates in fibroblasts to titers comparable if not superior to those attained by strain 
AD169 (51).  Even so, there remains a possibility that, like pseudorabies virus, a class E genome 
might provide HCMV with a replication advantage in certain cell types.  For fibroblasts, at least 
this appears not to be the case.  While it would be of interest to evaluate replication efficiencies 
in other cell types such as epithelial and endothelial cells, the genetic background of HB15ΔL/S 
and HB15Tn7∆k does not permit efficient entry into such cell types due to a mutation in UL131 
(50, 146).  Deletion of b'a'c' from a strain with broad-tropism will be needed to evaluate the 
importance of a class E genome in other cell types.   
In recent years a possible evolutionary advantage has been proposed for retention of 
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inverted or direct repeats, as such repeats may allow genomes to quickly regain an optimal 
genome length after acquiring or losing sequences (28).  This was suggested partly by the 
observation that during passage in vitro both strain AD169 and the varS variant of strain Towne 
appear to have lost up to 15.5-kb from UL, yet genome length remained essentially unchanged 
due to compensatory enlargements of the bʹ′ repeats (109).  Thus, in theory, modulating the 
length of inverted repeats could quickly compensate for loss or acquisition of sequences.  
There are several practical uses for HB15ΔL/S or similar deletion mutants.  Deletion of 
the 13-kb b'a'c' region allows relatively large insertions of foreign sequences for vaccine vector 
or gene expression purposes.  Moreover, HB15ΔL/S contains an attTn7 site that facilitates rapid 
site-specific insertion of foreign sequences by Tn7-mediated transposition (49).  In addition, 
because HB15ΔL/S virion DNA lacks internal junctions, circular or concatemeric DNA can be 
differentiated from virion DNA by the presence of terminal junctions.  Assays based on detection 
of such junctions may be useful for in vitro studies of HCMV genome circularization, latency, or 
persistence.  In our investigations, HB15ΔL/S has been invaluable for probing the molecular 
mechanisms of DNA packaging inhibitors (Chapter 5) and mutagenic analysis of HCMV DNA 
cleavage/packaging signals (148) using a system analogous to one constructed in murine 
cytomegalovirus (149).  Such studies are intractable in the context of the isomerization-
competent genome. 
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CHAPTER 5:  The internal junction of HCMV is essential for the 
formation of the supergenomic species Monomer-Plus 
 
Background 
HCMV contains a large double-stranded DNA genome that is divided into two major 
genomic segments designated long (L) and short (S).  Each segment is comprised of unique 
sequences (UL and US respectively) flanked by inverted repeats; UL is flanked by b/bʹ′ sequences 
and US is flanked by c/cʹ′ sequences.  Bracketing the sequence repeats are a sequences of about 
553 bp in length (136) (Figure 25).  The a sequences are believed to contain cis-acting DNA 
packaging signals.  Packaging begins with the short end translocating into the capsid and 
continues until almost the entire 230-kb genome has entered the capsid.  At this point, a headful 
restriction is satisfied and the terminase is authorized to cleave the viral DNA at the next 
packaging site that it encounters.   
How the halogenated benzimidazole, BDCRB and TCRB, inhibit genome maturation 
remains poorly understood.  They clearly do not impair concatemer synthesis and therefore do 
not act by blocking the viral DNA polymerase, as is the case for other HCMV antivirals.  Rather, 
these compounds impair the formation of monomeric DNA from the concatemer, suggesting that 
they somehow interfere with the DNA cleavage and packaging pathway.  Consistent with this, 
mutations that confer resistance to these compounds map to the HCMV genes encoding two of 
the terminase subunits UL89 and UL56. 
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Figure 25:  HCMV genome structure.  Shown is a schematic of the HCMV genome where 
boxes represent a,b, and c sequence repeats and aʹ′, bʹ′, and cʹ′ represent their inverted 
(complementary) sequences. 
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Monomer-plus model 
A feature common to inhibition by both BAY 38-4766 and the halogenated 
benzimidazoles is formation of a supergenomic species of viral DNA called "monomer-plus" 
(M+).  M+ has an apparent size of 270-kb (compared to 230-kb for the HCMV genome).  Little 
is known about its structure or its mechanism of formation; however, other and I have noted that 
the apparent 270-kb size is consistent with M+ being an HCMV genome with an extra S segment, 
or a S-L-S structure.  As shown in Figure 26, the L segment is 190-kb and the S segment is 40-kb.  
Hence, an S-L-S structure would have a size of 40+190+40 = 270-kb.  Based on this structure a 
simple model for M+ formation was developed (77).  The model describes under normal 
conditions cleavage occurs after entry of one S and one L segment into the capsid, drug 
treatment causes the normal cleavage site to be skipped such that an additional S segment is 
packaged; cleavage occurs at the next cleavage site that is encountered, the L/S junction of the 
penultimate genome in the concatemer (Figure 26). 
The model makes three predictions: (i) the left end of the genome should not be present 
on M+ DNA; (ii), M+ formation should depend on the presence of the internal junction; and (iii), 
M+ DNA should at least transiently be packaged within capsids.  Previous work confirmed that 
M+ contains right but not left genomic ends (77). This is also consistent with work by 
Underwood (143) showing that in the presence of BDCRB, the left end is almost undetectable 
but is restored when BDCRB is removed. Elucidation of the structure of M+ and its mechanism 
of formation will provide valuable insights that will further our understanding of herpesvirus 
DNA packaging as well as the mechanism of action of the "maturational inhibitors" BAY 38-
4766 and the halogenated benzimidazoles.  The focus of this Chapter is to test the hypothetical  
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Figure 26:  Monomer-Plus Model.  On the left is packaging of monomer DNA.  Beginning 
with the short segment (shown in blue) concatemeric DNA is translocated into the capsid by the 
packaging motor, terminase.  Concatemer DNA reaches almost a head full amount and this 
signals the terminase to cut the dsDNA at the next packaging signal to form a monomer.  For 
monomer-plus to form, packaging proceeds progressively as in monomer formation, but instead 
of cleaving the concatemer at the proper cleavage site, this site is skipped and another S segment 
is inserted into the capsid, creating a monomer plus structure.  
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model for M+ formation with experiments designed to (i) determine its dependence on the 
presence of internal cleavage sites, and (ii) evaluate its retention within viral capsids.   
Results 
M+ formation is dependent on an internal junction 
According to the M+ model, the formation of M+ is dependent on cleavage at the internal 
junction.  Therefore, the internal junction from HB15Tn7ΔK (Chapter 4) was removed.  To 
determine if the resulting virus, HB15∆L/S, could form M+ in the presence of BDCRB the virus 
was exposed to BDCRB.  The HB15∆L/S mutant and its wild type parental HB15Tn7ΔK were 
evaluated for M+ formation by infection in the presence or absence of 10 µM BDCRB.  Total 
cell DNA was harvested on day 7-post infection, separated by FIGE, and hybridized with a viral 
DNA-specific probe (77).  While the parental HB15Tn7ΔK made abundant M+ and reduced 
quantities of monomer in the presence BDCRB, M+ formation was absent in the mutant 
HB15ΔL/S (Figure 27).  This result supports the model by confirming that formation of M+ 
depends upon the presence of an internal cleavage site in the HCMV genome.  
HB15∆L/S is sensitive to BDCRB 
 The above results indicate that HB15∆L/S does not form M+ in the presence of BDCRB.  
This could be because it is somehow no longer sensitive to BDCRB.  To determine if loss of 
isomerization or removal of the internal junction affected the virus’s sensitivity to BDCRB, 
growth curves were performed in the presence or absence of 10µM BDCRB.  Figure 28 shows 
that HB15Tn7∆k (parental) and HB15∆L/S (mutant) are sensitive to BDCRB.  This confirms 
that sensitivity to BDCRB does not involve isomerization or require the presence of the internal 
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Figure 27:  M+ formation is dependent on an internal L/S junction. Cells were infected with 
the parental virus HB15Tn7ΔK or mutant HB15ΔL/S in the absence or presence of 10 µM 
BDCRB.  After 7 days, infected cell DNA was separated by FIGE and hybridized to detect viral 
DNA species.  Arrows indicate the positions of monomer (M) and M+. 
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Figure 28:  HB15ΔL/S is sensitive to BDCRB.  (A) HB15Tn7Δk grown in the presence (n) or 
absence (l) of 10 µM BDCRB.  (B) HB15ΔL/S grown in the presence (n) or absence (l) of 10 
µM BDCRB. 
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junction, and further confirms that the failure of HB15∆L/S to form M+ is not simply because 
the virus is no longer sensitive to the inhibitor. 
Analysis of C-capsids formed in the presence of BDCRB 
It is generally accepted that DNA packaged within capsids is protected from DNase 
digestion, and conversely, DNase-sensitive DNA is not packaged within capsids. However, 
studies on the effects of BDCRB on GPCMV revealed that in the presence of BDCRB, near-
genome length DNA is abundantly packaged within intranuclear capsids, yet this DNA was not 
protected from DNase digestion (94). This suggested that BDCRB somehow impairs the final 
capsid "sealing" step such that DNA may be contained within capsids yet remain DNase-
accessible.  The proposed mechanism for HCMV M+ formation suggests that M+ is at least 
transiently packaged within capsids.  
To determine if DNA-containing C-capsids are formed in the presence of BDCRB, cells 
were infected for four days in the presence or absence of BDCRB and fixed and sectioned for 
TEM.  The results revealed that there are significant numbers of C-capsids present in infected 
cells treated with BDCRB (Figure 29).  Thus as for GPCMV, BDCRB does not block the 
packaging of DNA into HCMV capsids.  Given that FIGE studies suggest that very little 
monomer is present in BDCRB-treated/infected cells, it is possible that M+ is within C-capsids 
but that these capsids are "unsealed" and will not protect M+ from nucleolytic digestion.  
I therefore conducted an experiment similar to one used to show that GPCMV DNA is 
packaged within "nuclease-permeable" capsids (94). MRC5 cells were infected with HCMV in 
the presence or absence of 20 µM BDCRB.  The cells were harvested three or seven days post 
infection.  Lysates were equally divided and one-half treated with DNase while the other half 
was treated with EDTA and kept on ice to block endogenous nucleases.  The samples 
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Figure 29:  Capsid formation in presence or absence of BDCRB.  Human MRC5 cells were 
infected with virus HB15Tn7ΔK and were either not treated with drug (top) or treated with 
20µM BDCRB (bottom).  After 4 days the cells were fixed and examined by TEM.  The white 
arrows indicate C-capsids, yellow arrows A-capsids, red arrows B-capsids. 
No BDCRB
20 µM BDCRB
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were analyzed by TEM (Figure 30).  Unfortunately, it was difficult to differentiate B- from C-
capsids in these samples, so capsids were classified as A or B/C. In the presence of no BDCRB 
and no nuclease, the percent of A-capsids was 12% of total capsids counted (Table 5).  Addition 
of BDCRB did not alter total A-capsids as the percent of A-capsids remained 17%.  However, in 
capsids treated with nuclease and no drug, total A-capsids increased to 49%. Capsids treated with 
BDCRB and nuclease showed an increase in A-capsids to 76%.  While failure to differentiate B- 
and C-capsids make unambiguous interpretations difficult, this result is consistent with formation 
of capsids in the presence of BDCRB that fail to protect their DNA from nuclease digestion and 
hence are “converted” to A-capsids.  This suggests that the capsids are not completely sealed and 
allow nuclease to enter the capsids and degrade the viral contents. 
I cannot, from these experiments, determine what DNA is present in BDCRB-treated C-
capsids.  However, previous unpublished data from the McVoy laboratory (personal 
communications M. Mondello) showed that M+ and all infected viral DNA species formed in 
presence of 20 µM TCRB are nuclease sensitive (Figure 31).  Taken together these results 
suggest that viral DNA continues to be packaged into C-capsids in the presence of BDCRB or 
TCRB, but that this DNA is not protected from nuclease digestion. 
Discussion 
Our model for M+ formation proposes that, in the presence of BDCRB, terminase fails to 
recognize the proper cleavage site.  Continued packaging results in an additional S segment 
entering the capsid before a second cleavage site at the L/S junction is encountered.  Cleavage at 
this site results in release of an S-L-S DNA species within the capsid, which we propose is M+.  
The model predicts the following: (1) no left terminal ends should be found on M+ DNA, (2), 
M+ DNA should enter capsids at least transiently, (3) and formation of M+ would 
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Table 5: Effects of BDCRB and nuclease on A-, B-, and C-capsid frequencies. 
Treatments 
% of Capsids* 
               A                                         B & C      
No nuclease 
No drug 12% 88% 
BDCRB 17% 83% 
Nuclease 
No drug 49% 51% 
BDCRB 76% 24% 
*Capsids were classified as A or B/C based on morphology as B and C capsids were difficult to 
differentiate.  Percentages are cumulative for ten fields of view examined for each group. 
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depend on the presence of internal junctions.  The first prediction has been confirmed previously 
(77).  Here, I have confirmed the third prediction by demonstrating that M+ formation does not 
occur in a virus that lacks an internal junction.  While I were unable to definitively demonstrate 
M+ DNA is present within C-capsids, I did show that C-capsids are formed in the presence of 
BDCRB, indicating that, like GPCMV, this class of inhibitors does not block DNA packaging, 
per se, but blocks the proper cleavage of genomes.  I further indirectly showed, that DNA 
packaged into capsids in the presence of BDCRB is sensitive to nuclease, as the percentage of 
capsids that were empty (A-capsids) increased dramatically when nuclease was added to infected 
cell lysates, as compared to mock nuclease treatment.  This was also consistent with prior data 
that TCRB treatment of HCMV infected cells renders all viral DNA species, including M+, 
sensitive to nuclease treatment. 
 Taken together, these results support our model for M+ formation and suggest that the 
halogenated benzimidazoles do not impair DNA translocation so much as alter cleavage site 
selection and hence result in packaging of abnormal DNA species within capsids that 
subsequently fail to mature to the point of protecting their contents from DNAse.  The reasons 
for the latter are unclear, but given recent studies implicating HSV-1 UL25 in stabilizing HSV-1 
C-capsids, it would be interesting to compare the protein composition of HCMV C-capsids 
formed in the presence or absence of BDCRB to determine if UL77 (homolog of HSV-1 UL25) 
or other proteins are absent when BDCRB is present.  Because the effects of BDCRB are 
reversible (8, 77), experiments to determine if restoration of UL77 or other proteins found 
coincides with BDCRB removal and recovery of nuclease protection should be feasible.  If so, 
M+ DNA could be trapped within a subpopulation of nuclease-resistant capsids, clearly 
demonstrating their existence within capsids. 
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Figure 30:  DNA packaged into capsids in the presence of BDCRB is sensitive to 
nuclease.  TEMs show cells infected with HCMV for four days in the presence or absence 
of BDCRB, then hypotonically lysed and either mock treated or treated with nuclease prior 
to fixation.  White arrows denote B- or C-capsids. 
20 µM BDCRB + nuclease
No BDCRB
No BDCRB + nuclease
20 µM BDCRB
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Figure 31:  M+ is nuclease-sensitive.  Cells were infected in the presence or absence of 10 µM 
TCRB for 6 days and lysed.  Lysates were either mock treated or treated with nuclease before 
DNA extraction and separation by FIGE.  Viral DNA species (Towne strain) were detected by 
Southern hybridization using probe pON2333 (unpublished data courtesy of Melissa Mondello). 
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CHAPTER 6:  Peptides from Cytomegalovirus UL130 and UL131 
Proteins Elicit Epithelial Entry Neutralizing Responses 
Comparable to Natural Infection and Capable of Neutralizing 
Viral Entry into Mucosal Epithelial Cells 
Background 
Historically HCMV neutralizing activity was measured using fibroblasts as target cells.  
However, recent experiments demonstrate that antibodies to epitopes within a pentameric 
complex of gH, gL, UL128, UL130, and UL131 (gH/gL/UL128-131) can potently neutralize 
entry into endothelial, epithelial, and other cell types while having no effect on fibroblast entry 
(2, 45, 73, 147) (Appendix A-Entry Mediators).  This is because the gH/gL/UL128-131 complex 
is essential for entry into endothelial and epithelial cells but fully dispensable for fibroblast entry 
(50, 120, 147).  Indeed, mutations causing loss of UL128, UL130, or UL131 expression are 
sufficient to eliminate endothelial tropism (50) and occur within relatively few passages in 
fibroblasts (30).  Natural infection elicits very high titer neutralizing responses specific for 
epithelial cell entry and it has been proposed that antibodies against gH/gL/UL128-131 epitopes 
may comprise a significant component of this activity (29, 45, 73).  In contrast, epithelial entry 
neutralizing titers induced by the Towne live attenuated vaccine or the gB subunit vaccine were 
28- and 15-fold lower, respectively, than those induced by natural infection (29).  These results 
suggest that vaccine efficacy might be significantly improved by incorporating strategies to elicit 
high titer epithelial entry neutralizing antibody responses.  
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In this chapter, I address two questions relevant to the design of vaccine strategies and their 
potential effectiveness.  First, can antibodies targeting gH/gL/UL128-131 complex neutralize 
viral entry into tissues relevant to vaccine protection?  For example, mucosal and secretory 
antibodies that neutralize viral entry into epithelial cells of the oral or genital epithelium might 
be effective in preventing or reducing viral transmission to new hosts.  Second, will individual 
subunits be sufficient in a vaccine, or will more than one subunit, perhaps the entire complex, be 
necessary to elicit the desired neutralizing responses?   
Results 
A functional gH/gL/UL128-131 complex is required for efficient HCMV entry into primary 
epithelial cells from mucosal tissues 
To determine the role of gH/gL/UL128-131 in HCMV entry into primary epithelial cells from 
mucosal tissues, entry efficiencies of two GFP-tagged viruses (one expressing and one lacking 
the gH/gL/UL128-131 complex) were compared by measuring the number of GFP+ cells 
observed at different times after infection.  Strain AD169 is the standard laboratory/reference 
strain of HCMV.  During fibroblast adaptation, it is believed to have acquired a frame shift 
mutation in the UL131 gene that disrupts expression of the UL131 protein (50), and this prevents 
formation and virion incorporation of the gH/gL/UL128-131 complex (146).  The two viruses 
used here, HB15-t178b and BADrUL131-Y4, are both AD169-derived, but while HB15-t178b 
retains the UL131 mutation and hence fails to express a virion-associated gH/gL/UL128-131 
complex, repair of the UL131 gene in BADrUL131-Y4 restores UL131 expression and virion-
incorporation of the gH/gL/UL128-131 complex (145).  
As shown in Figure 32-A, the two viral inocula were matched for entry into MRC-5 
fibroblasts even as the inocula were serially diluted down to low levels.  Cells originating 
 
 
106 
 
Figure 32: BADrUL131-Y4 enters primary epithelial cells.  Matching inocula of HB15-t178b 
and BADrUL131-Y4 were 10-fold serial diluted and added to wells of 24-well plates containing 
confluent cultures of the indicated cells.  Cultures were monitored by fluorescence microscopy 
and photographed on the days indicated after infection.  Numbers on the left indicate infectious 
viral dose (pfu/well). 
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from genital mucosal tissues, including vagina, cervix, and foreskin, all displayed a pronounced 
requirement for gH/gL/UL128-131, as evidenced by high levels of GFP+ cells on day 3 
following BADrUL131-Y4 infection and a virtual absence of GFP+ cells from cultures that 
received matching inocula of HB15-t178b (Figure 32, panels B-D).  Similar data were obtained 
with airway epithelial cells from tonsil and bronchus (Figure 32 panels E and F).  Foreskin and 
bronchial epithelial cells appeared to support the full replication cycle of BADrUL131-Y4, 
resulting in viral spread, as evidenced by increased GFP expression in BADrUL131-Y4-infected 
cell cultures over time (Figure 32, panels D and F).  In contrast, the number of GFP-positive cells 
remained stable over time in BADrUL131-Y4-infected vaginal, cervical, and tonsillar epithelial 
cells (Figure 32, panels B, C, and E), suggesting a possible post-entry block to BADrUL131-Y4 
replication in these cells.  
Peptide immunogens elicit potent neutralizing activities in rabbits 
Naturally acquired humoral immunity is associated with efficacy in prevention and 
treatment of HCMV infections (93) (3, 156), a vaccine should match or exceed the levels of 
neutralizing activities induced by natural infection.  Animal antisera raised against components 
of the gH/gL/UL128-131 complex neutralize epithelial and endothelial cell entry (2, 45, 147), 
but the potency of these animal sera compared to those elicited by natural infection are not 
known.  Frances Saccoccio therefore determined if rabbit sera raised against peptides from 
UL128, UL130, or UL131 neutralize epithelial cell entry with neutralizing titers comparable to 
sera from naturally infected humans.   
The rabbit sera were evaluated using a GFP-based neutralizing assay similar to one 
developed to study sera from naturally infected or experimentally vaccinated humans (29).  
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Figure 33:  Peptide immunogens elicit potent neutralizing activities in rabbits.  The 
indicated dilutions of human sera or rabbit anti-peptide sera were incubated with 500 pfu of virus 
BADrUL131-Y4 for one hour, then used to infect ARPE-19 epithelial cells.  In the bottom row 
equal amounts of rabbit anti-UL130 and anti-UL131 were mixed before being assayed as for the 
other sera.  No serum was added to the wells in the right-most column.  Representative 
micrographs were taken with a fixed exposure five days post infection.   
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Briefly, ten-fold initial dilutions of sera were two-fold serially diluted, mixed with a fixed 
amount of virus BADrUL131-Y4.  After an hour incubation the mixtures were added to 
confluent monolayers of ARPE-19 epithelial cells.  The cultures were monitored daily by UV 
microscopy.  Consistent with our previous report (29), sera from two HCMV seronegative 
donors had no effect on epithelial entry, whereas seropositive sera from five naturally infected 
donors blocked epithelial entry to dilutions of 1:640 (Figure 33).  Rabbit antiserum to the UL128 
peptide failed to neutralize epithelial cell entry at any concentration (Figure 33 and data not 
shown).  Rabbit antisera to UL130 or UL131 peptides neutralized epithelial entry with activities 
slightly below the range defined by the seropositive sera; however, a 50:50 mixture of the anti-
UL130 and anti-UL131 sera neutralized viral entry to a level equal or superior to all of the 
seropositive human sera (Figure 33).  Consistent with previous reports, all three rabbit sera failed 
to neutralize fibroblast entry at any concentration (Figure 33 and data not shown).  
Antibodies to UL130 and UL131 peptides neutralize HCMV entry into primary epithelial cells 
from mucosal tissues 
The results from the first section provide genetic evidence that entry into airway and 
genital epithelial cells requires UL131.  To directly confirm that proteins comprising the 
gH/gL/UL128-131 complex must be physically present on the virion surface to facilitate viral 
entry into these cells, I determined the ability of rabbit anti-peptide sera to block viral entry.  As 
before, the three antisera had no effect on BADrUL131-Y4 entry into fibroblasts and the anti-
UL130 and anti-UL131 sera potently inhibited entry to ARPE-19 epithelial cells while the anti-
UL128 serum did not (Figure 34).  Entry into epithelial cells from cervix, foreskin, and bronchus 
was highly sensitive to neutralization by both the anti-UL130 and the anti-UL131 sera (Figure 
34) physically confirmed that entry into these cell types involves UL130 as well as UL131. 
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Figure 34: Antibodies to UL130 and UL131 peptides neutralize HCMV entry into primary 
epithelial cells from mucosal tissues.  Replicate amounts of BADrUL131-Y4 were mixed with 
no serum (ø) or 1:20 dilutions of the indicated rabbit anti-peptide antisera.  After one hour 
incubation the mixtures were added to confluent cultures containing the indicated cells and the 
cultures were monitored daily by fluorescence microscopy.  Photographs shown are from day 7-
post infection.   
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Discussion	  
Here, I observed that a functional gH/gL/UL128-131 complex is essential for efficient 
CMV entry into primary epithelial cells derived from both airway and genital mucosa, 
demonstrate that immunization of rabbits with short peptides derived from UL130 or UL131 is 
sufficient to achieve epithelial entry neutralizing titers superior to that of natural infection, and 
show that these sera are effective at blocking HCMV entry into mucosal epithelial cells.  Our 
results suggest that subunit or peptide immunogens may be effective in eliciting potent epithelial 
entry neutralizing responses and that successful immunization in this regard has potential to 
provide sterilizing immunity by blocking viral entry at mucosal surfaces. 
In previous studies, others found that sera from HCMV-infected humans have two 
distinct neutralizing activities – a moderate activity, comprised mostly of antibodies to gB, that 
neutralizes viral entry into fibroblasts, and a far more potent activity that neutralizes viral entry 
into epithelial cells (29, 45).  The antigen specificities of the latter have not been clearly 
established, but because both the gH/gL/UL128-131 complex and this neutralizing activity are 
specific to epithelial cell entry, the antibodies that comprise the epithelial entry neutralizing 
activity are presumed to target gH/gL/UL128-131.   
The above results further suggest that a vaccine that incorporates gH/gL/UL128-131-
epitopes to induce epithelial entry neutralizing activities might be effective at preventing viral 
acquisition through mucosal epithelia.  This presumes, however, that infection of mucosal 
epithelial cells is gH/gL/UL128-131-mediated and hence neutralizable with gH/gL/UL128-131-
specific antibodies.  To date, the majority of work on the mechanism and neutralizing activities 
against epithelial entry have used ARPE-19 cells, which are derived from the retinal pigment 
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epithelium of the eye.  The importance of gH/gL/UL128-131 for viral entry has also been 
confirmed for tumor cells of epithelial origin derived from breast, cervix, lung, and colon (146).  
Here, I evaluated HCMV entry into cells derived from tissues believed to be most relevant to 
HCMV acquisition – airway and genital mucosa – and in all cases found that entry is 
gH/gL/UL128-131-dependent.  I further showed using a subset of cell lines that entry can be 
blocked by antibodies to epitopes within the gH/gL/UL128-131 complex.  These results support 
the hypothesis that a vaccine that elicits epithelial entry-specific neutralizing responses in 
mucosal secretions may provide sterilizing immunity.   
Little is known about the neutralizing epitopes within the gH/gL/UL128-131 complex, 
and of central importance for vaccine design, it is unknown if conformational epitopes unique to 
the full gH/gL/UL128-131 complex will be required, or if one or two subunits will be sufficient 
to elicit neutralizing activities comparable to natural infection.  Some evidence suggests that 
neutralizing epitopes may often require multisubunit complexes.  A recently described panel of 
17 human monoclonals having potent neutralizing activities against epithelial entry 
predominantly recognize epitopes that require two or more subunits – only one of the 17 
antibodies reacted with an individual subunit (73).  In addition, viruses comprising the Towne 
vaccine express UL128 and UL131, while expression of UL130 (and hence assembly of the 
gH/gL/UL128-131 complex) is impaired by a C-terminal frame shift that alters the protein’s 
stability (99).  Yet, despite the presumed ability to express UL128 and UL131 in vivo, the Towne 
vaccine does not elicit potent epithelial entry specific neutralizing responses (29).  Thus, at least 
in this context, UL128 and UL131 are not sufficient. Alternatively, animal antibodies raised 
against individual UL128, UL130, or UL131 peptides or recombinant proteins do neutralize 
epithelial or endothelial cell entry, indicating that each subunit contains neutralizing epitopes (2, 
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45, 147).  However, potency of animal antisera relative to human immune sera has not been 
reported.  Frances and I observed that peptide epitopes within UL130 or UL131 can elicit 
epithelial entry neutralizing activities comparable to those induced by natural infection, and 
indeed, the combination of these two anti-sera results in neutralizing activity superior to those of 
human seropositive sera.  This suggests that the gH/gL/UL128-131 complex contains at least two 
potent neutralizing epitopes that do not require multisubunit complexes.  While further studies 
are needed to evaluate and compare various immunogens derived from the gH/gL/UL128-131 
complex, our results imply that single subunit immunogens have the potential to produce high 
titer epithelial entry neutralizing responses. 
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Chapter 7:  Discussion 
 
HCMV is an ubiquitous virus infecting up to 80% of the population by age 40 (40).  The 
virus can be devastating to immune compromised individuals causing a range of symptoms from 
a mononucleosis type infection to a severe organ disease that, left unchecked, can lead to death 
(97).  Transplant patients can contract HCMV from donor organ tissues that are positive for 
HCMV.  The virus can reactivate within the donated organ and the immunosuppressed patient 
will not be able to combat the virus and HCMV will be able to replicate and cause disease.  
HCMV has the ability to cross the placenta causing disease in the fetus.  The fetus can be born 
with asymptomatic or symptomatic disease (41, 132).  HCMV is the leading cause of congenital 
viral infection in the United States (106).  Current FDA approved antivirals can halt or slow 
HCMV replication but have undesirable effects on patients, such as neutropenia and 
nephrotoxicity.  A major concern is drug resistance from prolonged use of GCV, CDV, and FOS.  
The current approved drugs target the viral polymerase; this can cause problems with cross-
resistance when these drugs are used in combination with each other.  There is a need for new 
antivirals that target processes other than steps in the replication cycle.  One family of potential 
drugs is the halogenated benzimidazoles. 
The halogenated benzimidazoles were the first antivirals to target the cleavage and 
packaging of the viral genome (143).  These compounds are nucleoside analogs.  Nucleoside 
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analogs usually target DNA synthesis, but the halogenated benzimidazoles do not; rather, they 
target the viral terminase (68, 143).  Additional terminase inhibitors that are non-nucleoside 
analogs have also been identified (112, 142, 15, 153).  Although most of these compounds have 
not progressed beyond preclinical or phase I trials, they have furthered our understanding of 
cleavage and packaging and the involvement of terminase.  In the presence of the halogenated 
benzimidazoles, BDCRB and TCRB, DNA concatemer is formed, but the cleavage signals to cut 
the concatemer into monomers are no longer properly recognized (94).  In HCMV, the terminase 
complex is made up of three proteins, UL56, UL89, and UL51.  Using nuclear magnetic 
resonance (NMR) and molecular modeling, Couvreux et al. (24) produced a model of UL89 and 
its interaction with UL56.  Couvreux (24) observed the C-terminal domain of UL89 (aa 580-600) 
to be involved in endonuclease activity and helicase activity while UL56 helps with the cleavage 
of branch points contained within the concatemer.  Thoma et al. (137) determined this region to 
interact with UL56 and is required for viral maturation.  Mutations that confer resistance to 
BDCRB or TCRB have been mapped to UL89 and UL56 (68, 143) in HCMV (Figure 14) but do 
not map to these putative regions of interaction between UL89 and UL56, suggesting that these 
drugs may not disrupt subunit interactions.  In GPCMV, resistance is associated within the GP89 
terminase subunit (Figure 14).  Currently, no homologs or structure models have been found that 
contain these mutations (143). 
BDCRB affects HCMV and GPCMV differently (Table 6).  In GPCMV, BDCRB 
exposure results in ample amounts of monomer formed, but this monomer is truncated on the left 
end (94).  DNA is packaged into capsids, but the capsids are nuclease sensitive, type II genomes 
are formed, and egress out of the nucleus is inhibited (94).  GPCMV packaging under no drug 
conditions is believed to occur as in the HCMV model shown in Figure 7.  The terminase scans  
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Table 6:  BDCRB alters packaging and cleavage 
GPCMV HCMV 
Exclusive type II ends Exclusive type II ends 
Abundant 230-kb DNA is formed in the 
presence of BDCRB 
Very little 230-kb DNA is formed 
The genome is truncated at the left-end No left ends are found 
DNA is packaged into capsids but does not 
egress from nucleus 
Forms a novel DNA species of 270-kb 
(monomer +) 
DNA is not protected by nuclease  
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the concatemer for a proper cleavage site, makes an initial cleavage and begins to translocate the 
DNA into a preformed capsid.  Once a headful amount of DNA has entered the capsid, the 
concatemer is cleaved and the capsid is sealed.  Stabilization proteins are added to the capsid.  
The mature capsid exits the nucleus by an envelopment--development (83).  When GPCMV is 
exposed to BDCRB, packaging is altered (Figure 20-A).  The terminase scans the concatemer for 
a proper cleavage site.  The concatemer is cleaved and packaging begins.  As the headful 
requirement is reached, instead of cutting the concatemer at the proper cis sequences located 
within the terminal repeats, terminase cuts the concatemer prematurely (94).  This results in 
genomes containing truncated left ends and right ends containing at least one repeat (Figure 20-
B) (94).   
A GPCMV BDCRB resistant mutant, R-75, encodes a single amino acid change in GP89, 
homolog of HCMV UL89, has reiterated terminal repeats, and a large deletion.  The single 
amino acid change in GP89 falls within conserved region VI (Figure 14) (24).  According to 
Champier et al. (17) conserved region VI contains homology to phage T4 terminase large 
subunit gp17 (homolog to UL89) in a region involved with portal binding.  This suggests a 
possibility that BDCRB interacts with a region of GP89 involved with interaction with the portal 
and therefore may affect head-full sensing, as this is believed to be transmitted from the capsid to 
terminase via structural alterations in the portal.   
From these observations, a hypothesis for accumulation of repeats was developed in 
which the increased number of repeats occurred first in response to drug selection, creating a 
genome that was over length.  This forced a deletion in the HindIII E region in order to restore 
normal genome length.  The resulting genome has reiterated terminal repeats and a deletion.  The 
latter aspect of this hypothesis is consistent with previous work demonstrating that over length 
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genomes rapidly acquire spontaneous deletions that are frequently within the HindIII E region 
(28).  The model for formation of BDCRB resistance is shown in Figure 20-B. 
HCMV is altered differently in the presence of BDCRB.  According to Table 6, HCMV 
like GPCMV, only forms type II terminal ends (77).  Different from GPCMV, monomer 
production (230-kb) is reduced and a supergenomic species is observed called M+ (143).  M+ 
migrates at an apparent size of 270-kb (143).  In Chapter 5, Table 5 shows the increase of A-
capsids in the presence of nuclease, suggesting the DNA is not sealed in a capsid but is nuclease 
sensitive.  EMs showed packaged DNA inside of capsids.  Previous work looked for the left 
terminal end and found that is missing from M+ DNA (77).  BDCRB/TCRB resistance mutations 
have been found in UL89 and UL56 (68, 143).  From these results, BDCRB appears to cause the 
terminase in GPCMV to be less selective, causing premature cleavage, while in HCMV 
terminase is less efficient at recognizing the proper cleavage site, causing cleavage site skipping.  
In either case, these drugs appear to modify cleavage site recognition and therefore may interact 
with terminase DNA binding domains.   
From the structural differences between GPCMV and HCMV, a model was derived to 
describe the formation of M+ (Figure 26).  The M+ model suggests in the presence of BDCRB, 
the viral DNA is packaged into capsids but instead of cleavage occurring at the left terminal end, 
the appropriate cleavage site is skipped.  The next proper cleavage site occurs 40-kb further 
down the concatemer.  Cleavage at that site creates an S-L-S structure (40-kb +190-kb + 40-kb = 
270-kb).  GPCMV does not form M+ in the presence of BDCRB, why not?  HCMV contains an 
internal junction (L/S junction) as shown in Figure 5.  The junction divides the genome into two 
segments, a long segment 190-kb and a short segment 40-kb.  ).  GPCMV does not form M+ in 
the presence of BDCRB presumably because its genome does not contain an internal cleavage 
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site.  HCMV contains an internal junction (L/S junction) as shown in Figure 5.  The model 
makes the prediction that in HCMV M+ formation is dependent on the internal junction.  To 
address this question, the internal junction was deleted, creating virus HB15ΔL/S.  HB15ΔL/S 
shows slight growth impairment but retains sensitivity to BDCRB.  In the presence of BDCRB, 
HB15ΔL/S did not form M+ (Figure 27), supporting the model by confirming that M+ formation 
does require an internal cleavage site.  
The M+ model predicts that DNA enters capsids and therefore capsids may appear 
similar to C-capsids by EM.  However, the DNA that they contain is nuclease sensitive (94).  
The same experiment, as performed in GPCMV (94), was attempted to show that C-capsids are 
formed in the presence of BDCRB and their contents were nuclease sensitive.  In the presence of 
nuclease and BDCRB, there was an increase of A-capsids (Table 5), suggesting that nuclease 
permeable C capsids are formed in the presence of BDCRB.  It has not been formally 
demonstrated that M+ is present within C-capsids but prior studies from our laboratory showing 
that M+ is sensitive to nuclease digestion and is the major viral species present in TCRB-treated 
cells strongly suggests this to be the case.  These studies are consistent with previous work by 
Nixon et al. examining the effects of BDCRB on GPCMV (94) and supports the model of M+ 
formation.   
Taken together, these studies suggest that BDCRB does not affect the translocation of 
viral DNA into capsids but does affect the way the DNA is cleaved.  In GPCMV, the left end is 
truncated (cleavage occurs prematurely) while in HCMV the left end is skipped (cleavage occurs 
late).  Chapter 5 demonstrated that DNA continues to be translocated into the capsid, but the 
capsids were not properly sealed.  Removal of the internal junction in HCMV resulted in the loss 
of M+ formation.  From the work presented in Chapter 3 and 5, the working models for both 
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GPCMV and HCMV viral cleavage are supported.  Both models suggest that BDCRB is 
interacting with cleavage, either altering terminase recognition if the cleavage site or relaxing the 
stringency of that recognition.  Taken together this implies that BDCRB is interacting with the 
regions that control sequence specificity of the nuclease function of terminase.   
Recent reviews (72, 108) cite promising antivirals such as GW275175X, Bay 38-4766, 
and AIC246 (71, 112, 142, 153), which inhibit terminase.  The difficulties in getting a drug 
approved for human use along with development of potential antiviral candidates suggest that 
working to develop a vaccine would also be advantageous.  HCMV is an important pathogen in 
transplant patients and women of childbearing years.  To complicate the development of a 
vaccine, HCMV is a life-long disease that evades the immune system by becoming latent, but 
reinfection can occur even with a pre-existing natural immunity (47, 117).  The development of a 
CMV vaccine has been given a high priority by the Institute of Medicine’s report Vaccines for 
the 21st Century (134). One goal of a vaccine is to induce neutralizing antibodies that prevent 
HCMV from entering host cells.  Recent work has found that the viral proteins UL128, UL130, 
and UL131 are necessary for virus to enter endothelial and epithelial cells (50, 147).  This entry 
complex has been found to be important for entry into retinal pigment epithelial cells and tumor 
epithelial cells derived from breast, cervix, lung and colon.  But it had not been determined 
whether this entry complex is important for entry into epithelial cells of the oral or genital 
mucosa.  To examine if entry into mucosal epithelial cells that are not tumor derived is also 
dependent on this complex, epithelial cells from the cervix, vagina, foreskin, tonsil, and bronchus 
were infected with matched inocula from a virus containing the complex UL128, UL130, and 
UL131 or a virus that does not express a complete complex.  The virus with the complex entered 
the all of the mucosal epithelial cells studied far more efficiently than the virus lacking the 
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complex.  Therefore, viral entry into mucosal epithelial cells is gH/GL/UL128-131 dependent.  
Moreover, the data (Chapter 6) further show directly that antibodies to two components of this 
complex can block viral entry into mucosal epithelium cells.  This models in vitro how a vaccine 
might work in vivo, assuming that similar antibodies can be produced in saliva.  The results 
suggest that antibodies that block epithelial entry, if present in saliva, may be able to prevent host 
infection by blocking initial viral infection of cells comprising the oral mucosa.  
Current candidate vaccines do not induce high levels of antibodies that neutralizing 
epithelial cell.  Adding epitopes from the gH/gL/UL128-131 complex may provide these 
antibodies.  The fact that two peptides are capable of producing very potent epithelial entry 
neutralizing activities suggests that small linear neutralizing epitopes do exist in this complex, 
and therefore it may not be necessary to represent complicated, multisubunit-dependent epitopes 
in a vaccine.   
Both vaccine and antiviral development are important to help protect and defend 
immunecompromised patients from the devastating effects of HCMV.  Understanding of the 
basic mechanisms of viral replication and packaging may be key to finding new targets for 
antiviral development.  New non-toxic antivirals could be extremely beneficial for treatment of 
congenital infections both in utero and postnatally.  An effective vaccine could prevent maternal 
HCMV infections and eliminate the devastating effects of congenital HCMV infections. 
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APPENDIX A 
Packaging and Cleavage Homologs 
 
 
 
 
HCMV HSV-1 Function 
UL56 UL28 Terminase subunit 
UL89 UL15 Terminase subunit 
UL104 UL6 Portal 
UL51 UL33 Terminase subunit 
UL52 UL32 May play a role in targeting capsids to replication compartments 
UL77 UL25 Vertex binding/stabilization protein 
UL80 UL26 Precursor of maturational protease 
UL80.5 UL26.5 Precursor of capsid assembly scaffold protein 
UL83  pp 65 Major tegument phosphoprotein 
UL86 UL19 Major capsid protein 
UL85 UL18 Minor capsid protein 
UL48/49 UL36/UL35 Largest tegument protein/smallest capsid protein (UL48A) 
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Entry Mediators 
 
 
 
HCMV Function 
UL128 
UL130 
UL131 
Form a complex with gH: gL to mediate entry into epithelial, 
endothelial & dendritic cells 
gB The target of fibroblast entry neutralizing antibodies, used in a 
candidate subunit vaccine. 
gH:gL Essential for viral replication; thought to have a role in fusion/entry. 
gO Forms a heterotrimeric complex with gH, gL.  May be a chaperone to 
deliver gH/gL to virions. 
gM:gN This complex is common but non-essential in other herpesviruses.  The 
complex may be involved with the initial interaction of the virus and 
the cell as it also binds heparan sulfate proteoglycans.   
 
Adapted from Fields Virology (86) 
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APPENDIX B 
 
Glossary 
 
CPE:  Cytopathic effect is the change in the appearance in cultured cells in response to viral 
infection.  With HCMV cells round up, detach, and sometimes fuse. 
Concatemer:  Long continuous molecules of DNA linked together end to end.  In HCMV, 
concatemers are a string of viral genomes linked together head-to-tail. 
EBV:  Epstein-Barr virus, a causative agent of infectious mononucleosis.  Also called human 
herpesvirus 4. 
Endothelial cells:  Form the lining of blood vessels and regulate exchanges between the blood 
and surrounding tissues; usually surrounded by the basal lamina. 
Epithelial cells:  Cover the external surface or lining of a cavity. 
HHV-7:  Human herpesvirus 7, a member of the genus Roseolovirus, first described in 1990; 
closely related to HHV6. A widespread virus with a seroprevalence of over 90% by age 2. 
HHV6:  Human herpesvirus 6, a member of the genus Roseolovirus, a widespread virus with a 
seroprevalence of over 90% by age 2. 
HSV-1:  Herpes simplex virus 1 is the common cause of cold sores.  This virus travels to nerve 
cells and becomes latent in ganglia.  Latent virus can become reactivated by sunlight, stress, 
fever, or other stimuli and cause cold sores around the mouth.  Can also infect the eyes causing 
blindness. 
Kaposi’s sarcoma-associated herpes virus:  Human herpesvirus 8, a member of the genus 
Rhadinovirus, is associated with Kaposi’s sarcoma. 
MOI:  Multiplicity of infection is the ratio of the number of infectious virions to the number of 
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cells in an infection. 
Monomer:  A single genome, as found packaged in a virion. 
Pfu:  Plaque forming unit.  
PrV:  Pseudorabies virus, also called Suid herpesvirus 1, is an infection of mainly pigs, but cattle, 
horses, sheep, dogs, cats, foxes and mink can become infected.  In pigs it can cause spontaneous 
abortions.  In the other animals the disease is fatal.  It is a member of the genus Varicellovirus. 
Sepsis:  The state when pathogens are present in a tissue. 
Superinfection:  A host that has been infected by one strain, presumably acquired immunity, and 
is then infected by a second strain of the same virus or pathogen. 
UL54:  The HCMV gene that encodes the viral polymerase. 
UL97:  The HCMV gene that encodes for a viral protein kinase that is found in the nucleus.  It 
adds the first phosphate to ganciclovir.  Its role in HCMV replication is unclear. 
Unit genome:  Another name for monomer. 
VZV:  Varicella zoster virus or human herpesvirus 3 is the causative agent of chicken pox in 
children and shingles in adults.  Shingles is a painful reactivation of latent VZV. 
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